Exploring the role of microRNAs in airway smooth muscle biology and asthma therapy by Hu, Ruoxi
 




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 4:51:17 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12274596
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA 
   Exploring the role of microRNAs in airway smooth 









Committee on Higher Degrees in Biological Sciences in Public Health 
in partial fulfillment of the requirements 
for the degree of  
Doctor of Philosophy 
in the subject of 














© 2014  Ruoxi Hu 




Dissertation Advisor: Associate Professor Quan Lu                                                       Ruoxi Hu 
 
 
Exploring the role of microRNAs in airway smooth 






The pathophysiology of asthma is characterized by airway inflammation, remodeling and 
hyper-responsiveness. Phenotypic changes in airway smooth muscle cells (ASM) play a pivotal 
role in the pathogenesis of asthma. ASM cells promote inflammation and are key drivers of 
airway remodeling. While airway hyper responsiveness and inflammation can be managed by 
bronchodilators and anti-inflammatory drugs, ASM remodeling is poorly managed by existing 
therapies. Therefore, targeting ASM remodeling remains a challenge, and a deeper understanding 
of the molecular mechanism that regulates ASM phenotypes in asthma pathogenesis will 
facilitate the search for next-generation asthma therapy. MicroRNAs are small yet versatile gene 
tuners that regulate a variety of cellular processes, including cell proliferation and inflammation 
– two phenotypes that are often altered in asthmatic ASM. We thus hypothesized that 
microRNAs regulate ASM phenotypes in asthma and represent new targets for future therapy. In 
this thesis, we used a genomic approach that combined next-generation sequencing with 
functional cellular assays to characterize the role of microRNAs  in regulating airway smooth 
muscle function and drug response to conventional therapies. In Chapter 2, we identified miR-
10a as the most abundant microRNA expressed in the primary human airway smooth muscle 
(HASM) cells. Using an unbiased target identification approach, we identified several novel iv 
 
potential targets of miR-10a, including the catalytic subunit alpha of PI3 kinase (PIK3CA)—the 
central component of the PI3K pathway. We demonstrated that miR-10a directly suppresses 
PIK3CA expression by targeting its 3’ Untranslated region (3’-UTR). Inhibition of PIK3CA by 
miR-10a reduced AKT phosphorylation and blunted the expression of cyclins and cyclin-
dependent kinases that are required for HASM proliferation. In Chapter 3, we examined the 
effect of conventional asthma therapies on miRNA expression. While we did not find significant 
changes in miRNA levels, it remains to be determined whether microRNAs play a role in ASM 
tissue response to asthma therapy. Our study is the first to examine the role of microRNAs in 
ASM proliferation. Results from our study identified a novel microRNA-mediated regulatory 
mechanism of PI3K signaling and ASM proliferation. They suggest further that miR-10a is a 
potential therapeutic target to treat airway remodeling in asthma. 
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Introduction   2 
 
Asthma 
Asthma is a common chronic airway disease prevalent in both developed and developing 
countries. It affects people of all ages and ethnic backgrounds. The prevalence of asthma is rising 
and by 2025 it is estimated that 400 million people worldwide will be diagnosed with asthma [1-
3].   
The clinical features of asthma include intermittent wheezing, cough, breathlessness and 
airway hyper-responsiveness to external stimuli [2]. These clinical conditions are believed to 
result from chronic airway inflammation and tissue remodeling [4, 5]. Airway inflammation is 
associated with a TH2 immune response that stimulates airway infiltration of eosinophils, mast 
cells and TH2 lymphocytes, as well as elevates IgE levels. Airway remodeling is characterized 
by epithelial alteration, fibrosis, goblet cell hyperplasia, neovascularization, smooth muscle 
hypertrophy and hyperplasia [4, 6, 7], and has been found in asthma of all degrees of severity 
and in both small and large airways.  
 
Conventional asthma therapy 
Continuous research efforts have offered great insights that link clinical features of 
asthma with biological pathways [2]. Two categories of asthma therapies were developed based 
on the molecular understanding of the disease pathogenesis. The first class, bronchodilators, 
target airway relaxation and the second class are anti-inflammatory drugs [8-10].  
Beta-agonists (β-agonists) are the most commonly used bronchodilators in the treatment 
of asthma [1-3]. They bind to β2-adrenergic receptors expressed on airway smooth muscle (ASM) 
cells to activate G-protein signaling that leads to an increase in cyclic adenosine monophosphate 
(cAMP) production and bronchodilation [11, 12]. There are two types of bronchodilators: (1) 3 
 
short acting β-agonists (SABAs), which are used by virtually all asthmatic patients as a rescue 
treatment in episodes of acute bronchoconstriction; and (2) long acting β-agonists (LABAs), 
which are usually prescribed together with inhaled corticosteroids (ICS)  to control symptoms 
among severe asthmatics[3].  
Inhaled corticosteroids (ICS) are another class of drug that is been widely used to treat 
asthma. Corticosteroids exhibit powerful anti-inflammatory and immunosuppressive properties 
and are used to treat a variety of inflammatory diseases such as asthma, COPD and interstitial 
pulmonary fibrosis [9, 13, 14]. Corticosteroids exert their anti-inflammatory effect by binding to 
and activating the glucocorticoid receptor (GR). Activated GR mediates anti-inflammatory 
effects through several different mechanisms.  Activated and dimerized GR can bind to DNA 
directly at sites known as glucocorticoid response elements (GREs) and negative GREs.  GREs 
are found in the promoters of anti-inflammatory genes and binding of GR is associated with 
increased transcription [15-17]. Conversely, binding of activated, dimerized GR to negative 
GREs mediates transcriptional repression, and negative GREs are found in pro-inflammatory 
genes [18]. GR can also exert an anti-inflammatory effect by binding to and inhibiting pro-
inflammatory transcription factors, thereby lowering the transcription of inflammatory 
genes[19].  
 
Limitations of current asthma therapy 
Although β-agonists and corticosteroids have been around for more than 50 years, these 
current treatments are insufficient in managing severe asthmatic symptoms due to treatment-
unresponsiveness following prolonged treatment [9, 10]; therefore, identification of new 
therapeutic targets that improve the efficacy of the existing therapy is needed.  4 
 
There are two major limitations associated with the β-agonists treatment: (1) high 
variability in bronchodilator response among patients and (2) the loss of β-agonist efficacy 
among severe asthmatics due to a potential loss in functional β2-adrenergic receptors (β2AR) [10, 
20]. Efforts in Pharmacogenetics have focused on studying the β2-adrenergic receptor gene 
(ADRB2) to explain the widespread variability in bronchodilator response [21, 22]. The ADRB2 
gene is an intron-less gene, which has been sequenced in multiple ethnic groups to identify single 
nucleotide polymorphisms (SNPs). Earlier bronchodilator association studies have mainly 
focused on analyzing the association between coding SNPs of ADRB2 and bronchodilator 
response [23-25]. However, contradictory findings have been reported by different groups and 
the irreproducibility of coding block SNP associations in the ADRB2 gene have prompted 
investigation into the regulation of ADRB2 function [20]. Therefore, looking into genetic 
variants within regulators of β2AR function may provide new clues to explain the inter-
individual variability in bronchodilator response. 
Another major limitation associated with β-agonist usage is the loss of efficacy in 
prolonged treatment, which is most prevalent and problematic in severe asthma management 
[10]. This loss in efficacy of the treatment is believed to be caused by β2AR down regulation 
[12]. β2AR down regulation is a natural process of the cell to prevent excessive signaling. The 
activation of β2AR signaling by β-agonists is attenuated by desensitization of the receptor. Once 
activated, the receptor is quickly phosphorylated which leads to the recruitment of various 
adaptor proteins that in turn recruit E3 ligases to ubiquitinate the receptor.  Ubiquinated β2AR is 
a target for proteasome degradation. This receptor down regulation process is heavily regulated, 
and multiple key regulators have been uncovered over the past decade [12, 26-29]. Hence, a 
targeted inhibition of receptor down regulation could prevent excessive β2AR loss and improve 5 
 
the current β-agonist based asthma therapy. However, such strategy would require a thorough 
mechanistic understanding of the receptor down regulation process.  
   Similar to the limitations associated with β-agonist treatment, there is also a great degree 
of individual variability in patient response to ICS [30]. Most of patients with severe asthma are 
largely resistant to ICS treatments [8, 31]. To better understand the development of ICS 
resistance and to explain the widely observed variability in drug response, past research has 
focused on analyzing SNPs along the GR pathway and key regulators in the inflammation 
pathway. Strong associations have been found in corticotropin-releasing hormone receptor 1 
(CRHR1) [32]; T-bet, a key transcriptional factor for naï ve T-lymphocyte production [33]; and 
FCER2, a low affinity IgE receptor [34]. However, only a part of the phenotypic variation is 
explained by these SNPs [20, 30]. More studies are needed to identify other susceptibility factors 
that contribute to the heterogeneity in ICS response. Further mechanistic studies on the 
regulation of GR function are also useful to improve the efficacy of GR treatment within severe 
asthmatic patients. 
 
The role of airway smooth muscle (ASM) in airway hyper-responsiveness (AHR) 
A link between airway smooth muscle (ASM) and airway hyper-responsiveness (AHR) 
in asthma was first hypothesized two centuries ago [35]: In 1968, it was reported that bronchia 
are contracted during asthma attack that produces a wheezing noise in expiration which is not 
dependent on phlegm production. In mid-19
th century, it was documented that the bronchial tube 
is the only possible cause of asthma.  The same study documented that bronchial contraction is a 
consequence of spastic contraction of the fiber like cells which we now refer to as airway smooth 
muscle (ASM). AHR refers to excessive narrowing of the airway in response to outside stimuli, 6 
 
is a clinical hallmark of asthma. Now it is well recognized that ASM is the effector cell of the 
airway narrowing event. Hence, a deeper understanding of ASM biology could identify 
therapeutic targets in managing AHR. 
The importance of ASM in AHR arose from  a pivotal finding that ASM obtained from 
asthmatic patients release more histamine and respond more to contractile agonists, such as 
house dust and pollen, compared to non-asthmatics’ ASM [36]. Following the study, multiple 
groups have hypothesized that AHR can be caused by structural and functional changes in ASM 
[37-39]. Structural changes in ASM such as a change in muscle mass and mechanical properties 
of ASM have been explored extensively as potential contributors to AHR. A landmark study by 
Lambert et. al concluded that the increase in smooth muscle mass was potentially the most 
important structural change in determining AHR [40]. This conclusion has been supported by 
many later publications that show an increase in ASM mass is the predominate contributor to 
AHR and that the underlying causes of an increase in ASM mass are cell hyperplasia and 
hypertrophy [41-44]. Another branch of research has heavily investigated the mechanical 
properties of ASM and how they contribute to AHR. Some mechanical properties explored 
include: the velocity of ASM shortening, ASM force generation, and the effect of deep 
inspiration on muscle relaxation [44-47]. Comparing ASM cells from asthmatic and normal 
subjects revealed that asthmatic ASM cells exhibit greater maximal shortening and faster 
shortening.  These characteristics were found to be associated with increased expression of 
contractile proteins such as myosin light chain kinase, an enzyme that mediates the formation of 
the actin-myosin cross bridge during muscle contraction [45]. A follow up study showed 
asthmatic ASM has greater myosin heavy chain isoform (SM-B), which is known to propel faster 
actin movement and thus a faster contraction [48]. These data suggest that a change in both ASM 7 
 
mass and the expression of the proteins that make up the contractile machinery in ASM cells can 
lead to changes in the contractility of ASM cells and ultimately result in a change in AHR. 
 
The role of ASM in airway remodeling 
With the accumulation of studies in smooth muscle biology, ASM are now known to be 
phenotypically very plastic in response to changes in the micro-environment. These phenotypic 
changes may ultimate lead to the airway remodeling observed in asthma [49]. During asthma 
pathogenesis, ASM cells are known to constantly undergo changes in its proliferative phenotype 
[49]. 
Increased ASM mass is a direct result of a change in ASM’s proliferative phenotype and 
is believed to be the most important component of the airway wall remodeling process in asthma 
[44,50, 51]. The mechanisms underlying increases ASM mass involve both hyperplastic and 
hypertrophic changes in ASM cells [42]. An increase in ASM cell number could be a direct 
result of decreased ASM cell apoptosis or an increase in ASM cell proliferation. Research efforts 
have mainly focused on the cell proliferation. Mediators of ASM cell proliferation fall into three 
categories: agonists that activate receptor tyrosine kinase (RTK), agonists that activate G-protein 
coupled receptors (GPCR), and pro-inflammatory cytokines. Polypeptide growth factors such as 
platelet derived growth factors (PDGF) and epidermal growth factor (EGF) are mitogens that 
bind to RTKs. The activation of RTKs then signals through downstream effectors such 
phosphoinositide 3’-kinase (PI3K) and mitogen-activated protein kinase (MAPK) to increase 
DNA synthesis and cell proliferation [43, 52]. Αlpha-thrombin (α-thrombin) and endothelin-1 are 
examples of agonists that bind to GPCRs and increase cell proliferation via GPCR-mediated 
activation of PI3K [53, 54]. A third group of newly emerged mitogens are inflammatory 8 
 
cytokines such as interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α). These 
cytokines signal through surface glycoproteins that are coupled to multiple non-RTK receptors to 
increase cell proliferation, such as Src family members, mitogen-activated protein kinase 
(MAPK) and Janus kinase (JAK)/ signal transducer and activator of transcription (STAT) 
systems [55]. Although it is tantalizing to speculate the importance of inflammatory cytokines in 
regulating cell proliferation, their effects on proliferation is very modest compared to other 
categories of mitogens [56-58]. 
As mentioned above, another way to explain ASM hyperplasia is that it could result from 
dysregulation in apoptosis. However, little is known about the exact role of apoptosis in ASM 
hyperplasia and remodeling since only a few studies have approached ASM cell survival and 
their response to apoptotic signals. Endothelin-1 [59], chemokines such as CCL3, CCL5, CXCL8 
[60] and some extracellular matrix (ECM) proteins such as fibronectin and collagen I [61] are all 
known to induce apoptosis in ASM cells. We also know that ASM cells express death receptors 
like TNFR1, FAS (TNFRSF6) and stimulation of ASM cells with either TNF-α and Fas ligand 
can induce apoptosis [62, 63]. However, all of these studies were conducted in vitro on healthy 
ASM cells and the importance of these signaling pathways in asthmatic ASM cell survival 
remains unknown.  
Unlike ASM cell hyperplasia, evidence for ASM cell hypertrophy remains a matter of 
debate [64, 65]. Increased ASM cell size has been reported from studies looking at ASM samples 
from intermittent, moderate, severe, fatal asthma. No ASM cell hypertrophy was found among 
mild to moderate asthma patients [65], and therefore, ASM hypertrophy is believed to be a 
phenotype only seen in severe asthma patients.   Several pathways regulate ASM cell 
hypertrophy, such as the activation of the mammalian target of rapamycin (mTOR) pathway [66] 9 
 
and the inhibition of the glycogen synthase kinase 3 beta (GSK-3β)  pathway [67]. However, the 
pathological relevance of these pathways in the context of asthma requires further investigation. 
  In addition to increased ASM mass, studies suggest that ASM cells isolated from 
asthmatics secret extracellular matrix (ECM) proteins in vitro which explains the increased ECM 
proteins depositions of collagen I, III and V, fibronectin and lamnin observed in asthmatics [68, 
69].  Fibronectin and collagen I have been reported to promote ASM cell growth while lamnin 
inhibits ASM cell growth [70]. The increase in ECM is believed to further contribute to the 
thickening of the airway wall and remodeling. ECM influences cell proliferation and is 
postulated to be a positive feedback mechanism for promoting ASM cell growth and further 
thickening of the airway wall [71]. An in vitro experiment suggests that ASM cells proliferate 
faster on fibronectin or collagen I coated plates than standard polystyrene [71]. Asthmatic ASM 
cells in vitro secret more perlecan and collagen I and less laminin-α1, again strengthening the 
argument of dysregulated ECM production by ASM in airway remodeling [71]. In addition to 
ECM’s effect on cell proliferation, ECM has also been linked to promoting the synthetic 
phenotype of ASM. ECM substrates like fibronectin and type I collage were found to enhance 
IL-13-dependent ASM secretion of eotaxin, a potent chemokine that stimulates the migration of 
eosinophils to the lung during lung inflammation [72].  
 
The Role of ASM in airway inflammation 
 While early ASM studies focused on airway remodeling and contractility, more recently 
attention has shifted to its role in the regulation of airway inflammation. A growing body of 
evidence consistently demonstrates that ASM is more than a target of the inflammatory process; 
ASM displays immunomodulatory properties through its synthetic phenotype and its expression 10 
 
of cell surface molecules such as integrins and toll like receptors [73, 74]. ASM acts in a positive 
feedback mechanism with mast cell and T lymphocytes to propagate the inflammation cycle. 
Growing evidence suggests the asthmatic ASM layer is infiltrated by mast cells and that 
this specific pathological event is unique to asthma and is absent from other lung inflammatory 
diseases such as bronchitis [75-78]. The infiltration of mast cells into ASM tissue is believed to 
be caused by the secretion of chemotactic factors, such as CXCL family proteins, by the ASM 
cells [75]. Upon activation, mast cells then release tryptase and proinflammatory cytokines such 
as TNF-α that in return stimulate ASM cells to produce TGF-β1. In turn, ASM cells differentiate 
towards a more contractile phenotype, which is coupled with increased expression of α-SMA [79, 
80]. The number of mast cells found within the ASM layer of the airway positively correlates 
with the degree of AHR and the amount of α-SMA. Therefore, there is in vivo relevance of the 
mast cells’ effect on the ASM cell phenotype [80, 81]. 
T cells alter the contractile phenotype of ASM resulting in changes relating to lung 
inflammation and AHR [82, 83]. Activated T cells adhere to the surface of human ASM cells via 
adhesion molecules expressed on the cell surface. The adherence leads to an increase ASM’s 
responsiveness to contractile agonists such as acetylcholine and impairs ASM’s relaxation 
responsiveness to isoproterenol [84]. T cells were also found to drive ASM remodeling by 
enhancing ASM hyperplasia. Close contact of CD4+ T cells with ASM cells causes increased 
ASM proliferation and DNA synthesis as well as a decreased rate of apoptosis [82]. Furthermore, 
the number of infiltrated T cells observed in asthmatic ASM correlates with ASM mass in vivo 
[83]. On the other hand, ASM cells are also known to alter functional properties of T cells. 
Direct contact between CD4+ T cells and ASM cells enhances T cell survival [83]. In addition, 
ASM cells are able to present super antigens on the cell surface via MHC proteins to activate 11 
 
resting CD4+ T cells, which results in greater release of IL-13 and a subsequence increase in 
ASM contractility[85]. 
 
Pivotal role of ASM in asthma pathophysiology 
  The pathophysiology of asthma is characterized by AHR, lung inflammation and airway 
remodeling [2,86, 87]. AHR is defined by increased airway narrowing to a wide range of stimuli, 
which is responsible for recurrent asthma attacks and breathlessness. ASM is the main effector 
tissue that mediates AHR during an asthma attack [88]. It is apparent from evidence presented 
above that ASM cells undergo constant remodeling and contribute to the increasing severity of 
AHR-related symptoms [5,83, 89]. Lung inflammation involves the recruitment of various 
inflammatory cells including mast cells and T lymphocytes. ASM cells themselves are active 
immunomodulatory cells that promote inflammation and recruitment of inflammatory cells to the 
airway. ASM cells do this by expressing cell surface adhesion molecules and through its 
synthetic properties such as secreting ECM proteins [82,85, 90]. Airway remodeling is a 
dynamic process involving multiple layers of dysregulation, including alterations in epithelial 
cells, disruption of the complex interactions between inflammatory and ASM cells, enhanced 
ECM deposition and an increase in ASM cell mass. ASM cells are central to these processes and 
there are multiple levels of evidence showing that increasing ASM cell mass is the key driver 
behind airway remodeling and AHR [44, 50, 62, 68, 69]. While AHR and bronchial 
inflammation can be controlled by conventional therapies, ASM remodeling is not well managed 
by these same therapies [88, 91]. Therefore, targeting the thickening of ASM is a goal for future 
asthma treatments. In the future, research needs to focus on ways to prevent and reverse ASM 
remodeling. Hence, a deeper understanding of the molecular mechanisms that keep airway 12 
 
remodeling in check represents an area of new opportunity in searching for the next-generation 
asthma therapy. 
 
Non-coding RNAs and microRNAs  
  Over the past decade we have learned that protein coding genes only comprise 2% of the 
entire human genome and that the vast majority of the genome is transcribed into so-called “non-
coding” RNAs. [92]. In recent years, it has become increasingly evident that the non-protein 
coding portion of the genome plays important regulatory roles in development, physiology and 
disease pathogenesis [93]. The functional evidence of non-coding RNA is best studied in small 
non-coding RNAs called microRNA (miRNA). However, many other classes of non-coding 
RNA, such as long non-coding RNA (lncRNA), have also been shown to play important roles in 
disease progression [94, 95]. 
MiRNAs are the most widely studied class of non-coding RNAs. They average about 22 
nucleotides in length and have profound effects on the transcriptome by mediating post-
transcriptional gene silencing [94, 95]. The process of miRNA maturation involves enzymatic 
processing of primary miRNA transcripts by Drosha to produce a 70-nucleotide stem loop 
structured precursor miRNA. This precursor miRNA is then transported to the cytoplasm where 
it is further processed by Dicer into a 22-nucleotide double-stranded RNA molecule [96]. One 
strand of the double stranded RNA is the mature miRNA that is loaded onto the RNA-induced 
silencing complex (RISC).  As part of RISC, the miRNA mediates post-transcriptional inhibition 
by the imperfect 5’ binding of the miRNA seed sequence to miRNA-recognition elements (MRE) 
within the 3’ Untranslated Region (3’UTR) of target genes. As a result, the complimentary 
binding of miRNA to its target gene can lead to target mRNA degradation and/or translational 13 
 
inhibition [95, 96]. Computational analysis indicates that greater than 60% of the human genome 
may be regulated by miRNAs [97].  
Many of the identified miRNAs are evolutionarily conserved, and hence miRNA-
mediated gene regulation represents a conserved and complex regulatory network of biological 
processes [98]. Up to now, miRNAs have been shown to play crucial roles in the regulation of 
many important cellular functions such as cell proliferation, differentiation, apoptosis, 
inflammation and stress response [99-102]. Furthermore, expression profiling studies revealed 
that dysregulated miRNA expression is associated with multiple diseases ranging from cancer to 
chronic diseases such as cardiovascular disease [99,100, 103]. However, despite increasing 
awareness of the importance of miRNAs in basic cell functions and diseases, many of miRNA 
targets, functions and biological relevance are poorly understood. 
 
microRNA expression profiling  
In the human genome, there are a limited amount of miRNAs compared to mRNAs: there 
are believed to be ~1000 miRNAs, compared to ~30,000 mRNAs. Since one miRNA can 
regulate up to several hundred target genes, a small number of miRNAs may still have 
substantial influence on a gene expression network overall [104]. Hence, miRNA expression 
analysis may contain rich biological information as the variation in multiple pathways and genes 
may all captured in the expression differences in a small set of miRNAs. Expression analysis of 
miRNAs in different tissues can provide clues about their physiological functions. Identifying 
tissue specific miRNA can uncover novel biomarkers for diseases and open new therapeutic 
venues for treatment. It is increasingly evident that miRNAs exhibit tissue-specific expression 
patterns, which are often highly associated with their function. For instance, miR-1a was found 14 
 
to account for 45% of all miRNAs identified in the heart and it regulates multiple pathways that 
control cardiac remodeling [105, 106]. Similarly, miR-122a accounts for 78% of all miRs in the 
liver and controls multiple processes such as cholesterol metabolism, an important component of 
hepatic function [107].  
Over the past decade, a number of molecular biology tools have been developed to assist 
in miRNA discovery and quantitative expression profiling. Quantitative PCR (qPCR) is used to 
quantify the relative expression level of a miRNA to a housekeeping small RNA such as U6. 
This method is highly sensitive and can distinguish difference isoforms of miRNA to a single 
base pair resolution. However, qPCR is low throughput and suffers from low coverage due to 
reliance on primer based amplification, which is difficult to scale up and requires a prior 
knowledge of the miRNA sequence [108]. Microarray-based miRNA profiling offers higher 
throughput but poorer accuracy, because detection depends on the hybridization efficiency of 
miRNA to the probes printed on the array. Variations in the measurement can be attributed to 
many sources such as non-specific binding, temperature and miRNA expression level. Therefore, 
proper normalization is critical and can often be the biggest source of variations in data [109]. To 
overcome coverage, specificity and throughput problems, next-generation small RNA 
sequencing was developed and it is a technology that utilizes massive cDNA sequencing which 
allows for the direct measure of different small RNA species in a given sample. This new 
technology offers several advantages over the previous array based approach. First, detection of 
small RNA is not limited to the known microRNA database, allowing for the miRNAs discovery. 
Unlike the hybridization based approach, direct sequencing offers single base pair resolution 
providing for accurate profiling of each variant of the same miRNA species. Lastly, RNA 15 
 
sequencing offers a larger dynamic detection range: both transcripts that are highly expressed 
and lowly expressed can be more accurately identified compared to other methods [110].  
 
microRNA target gene identification 
Due to the advancement in RNA sequencing technologies, over 1500 miRNAs have been 
identified. However, the functional characterization of each miRNA remains a challenge because 
one miRNA can have up to hundreds of evolutionarily conserved gene targets [111]. Unraveling 
the biological significance of each miRNA is further complicated by the fact that several 
different miRNAs can target the same gene [112].  
Computational algorithms have been the major prediction tool to identify putative 
miRNA target genes. These algorithms rely on the principle that most miRNAs mediate gene 
silencing via the binding of its seed sequence (the sequence 2-7 nucleotides from the miRNA 5’ 
end) to the 3’UTR of the target mRNA [113]. The algorithm scans the 3’UTR of all known 
mRNA and comes up with a list of potential gene targets with the probability of targeting.  The 
probability is determined based on the level of base pair conservation  [111]. The most 
commonly used target prediction software are: PicTar, TargetScan, miRana and miRGen. It is 
widely recognized that different algorithms yield different miRNA-mRNA pairing predictions 
and that a large number of predicted target genes are false positives (pairs that are statistically 
significant but cannot be verified using experimental methods) or false negatives (actual gene 
targets that are missed from the prediction software). Oftentimes the latter is more difficult to 
overcome because it requires a better understanding of the mechanism of miRNA target 
recognition. To test for false positives, an experimental approach is always needed. One common 
technique for validating miRNA targeting is to either overexpress or inhibit the miRNA and 16 
 
assess whether the predicted change in the protein level of the target mRNA shifts in the manner 
expected. To complement this assay, a 3’UTR assay is always required to confirm a direct 
molecular link between the miRNA and mRNA: the 3’UTR of the target mRNA is cloned into a 
luciferase reporter, the recombinant plasmid along with the miRNA of interest is co-expressed 
and luciferase activity is measured to demonstrate the binding of miRNA to the 3’UTR of target 
gene [114].    
 
Regulation of microRNA expression 
It is poorly understood where the primary transcript of each miRNA were first 
transcribed and what regulates the transcription of primary miRNA transcripts. miRNA 
transcription is likely regulated in a similar fashion to mRNA: by the binding of positive and 
negative transcription factors to the promoter region of a miRNA locus. miRNA transcriptional 
regulated is best studied in the context of cancer. The oncogenic transcription factor c-myc binds 
directly to a stretch of conserved sequence about 1.5kb upstream of the miR-17-5p cluster to 
regulate the entire mir-17-92 polycistron which is known to be oncogenic and promote tumor 
growth [115]. Tumor suppressor gene p53 was also found to regulate miRNA expression. P53 
can bind to consensus sequences in the promoter region of the miR-34 family and activate their 
expression to mediate cell cycle arrest and apoptosis [116-119]. 
miRNA transcription also appears to be regulated by epigenetic modifications and DNA 
methylation. This is demonstrated by a subset of miRNA genes residing near CpG islands [120]. 
The transcription of miR-148a, miR-34b/c, miR-9 and let-7a-3 are carefully regulated by their 
methylation status and DNA methyltransferases [120-122]. It is estimated that 5-10% of 
mammalian miRNAs are epigenetically regulated [120]. One dramatic example is miR-127, 17 
 
which was 50-fold up regulated following methyl transferase inhibitor treatment [123].  Another 
example includes the let-7a-3 locus, which was hypomethylated in lung adenocarcinoma tissue 
and extensively methylated in normal lung tissue. In this case, the miRNA expression is tightly 
regulated and its dysregulation could contribute to cancer progression [121]. 
Once transcribed, miRNAs are regulated at the processing level. A mass-spec analysis of 
flag-tagged Drosha revealed 20 distinct interacting proteins in addition to DGCR8, which binds 
to Drosha to activate it [124]. The processing activity of Drosha is tightly controlled by positive 
regulators such as RNA helicase p68/p72 [125], R-smads [126], p53 [127] and negative 
regulators such as nuclear factor 90/45 [128] and Lin28 [129]. 
Similar to Drosha, Dicer activity is also carefully regulated. The relatively low levels of 
pre-miRNA compared to pri-miRNA or mature miRNA suggest that Dicer is very efficient at 
processing pre-miRNA to mature miRNA. In contrast to Drosha which often requires co-factors 
to promote processing, Dicer regulation involves more inhibitory factors [130]. The best studied 
example is the processing of pre-miR-138. The pre-miRNA molecule is efficiently processed by 
Dicer in-vitro; however, the addition of HeLa cell extract inhibits Dicer activity, suggesting that  
cells express factors that specifically inhibit Dicer activity [131]. The amount of Dicer may serve 
as another control point to modulate miRNA expression. Altered expression of Dicer is observed 
in several types of cancer, for example Dicer expression is decreased in non-small-cell lung 
cancer [132], and increased in prostate tumors [133]. The discovery of Let-7 mediated negative 
feedback regulation of Dicer activity further demonstrated the complexity of Dicer regulation 
[134]. Much remains to be learned about the cellular consequences of altered Dicer expression 
and the biological significance of global change in miRNA expression.  
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 The role of microRNAs in Lung biology 
The lung has a specific miRNA expression profile and its miRNAs are shown to be 
important for lung development [135]. For example, a lung specific deletion of Dicer can lead to 
abnormal apoptosis and defective airway branching [136]. miR-17-92 is believed to regulate 
lung development, because its expression is high in embryonic lung and slowly decreases 
through development from fetus to adulthood [137]. This is further demonstrated by in vivo 
miR-17-92 knockout mice, which have no terminal bronchioles and have defects in lung 
epithelium differentiation [138]. In addition to miRNAs role in healthy lung development, a 
number of studies have implicated miRNA in a range of pulmonary diseases such as lung cancer 
[139, 140], asthma [141-143] and COPD[144, 145]. 
 
The role of microRNAs in asthma  
Asthma is characterized by both airway inflammation and remodeling. Several studies 
have implicated miRNAs in the negative feedback regulation of key inflammatory pathways 
[142, 146] and miRNAs also contribute to the control of extracellular matrix synthesis and tissue 
fibrosis [145, 147]. Therefore, it is conceivable that miRNAs play important roles in regulating 
asthma progression and specific miRNA targeted manipulation may provide new opportunities 
for asthma treatment.    
  Although miRNAs have been well studied in inflammation, only a few studies have 
explored the biological significance of miRNAs in regulating asthma-related inflammation. An 
animal model of house dust mite induced allergic airway inflammation was used to compare 
miRNA expression patterns between control and inflamed lung tissue. miRNA-16, -21, and -126 
were significantly up regulated in the inflamed group. Interestingly, intranasal administrations of 19 
 
anti- miR-126 attenuated airway hyper-responsiveness and decreased eosinophil and neutrophil 
recruitment as well as the secretion of IL-5, IL-13 [142]. This suggests miR-126 mediates airway 
inflammation. Another in vivo profiling study used the ovalbumin (OVA)-induced allergic 
asthma model in mice to measure miRNA expression profiles following short, intermediate and 
long term OVA exposure from whole lung RNA extract. More than 50 miRNAs were 
differentially expressed at different time points. miR-146b,  -223,  -29, -483, -574, -672 and -690 
were the most likely to participate in asthma pathogenesis according to pathway enrichment 
analysis [148]. Although most of the miRNA-mRNA target validation has yet to be performed 
by this study, this is the first large scale in vivo miRNA profiling covering the temporal change 
in miRNA expression from the initiation of the disease to a state of chronic airway inflammation. 
This large scale in vivo profiling experiment suggests that the molecular mechanisms underlying 
asthma pathogenesis are highly complex and it is likely to be regulated by multiple miRNA 
mediated pathways. 
miRNA’s role in asthma pathogenesis is also studied using cell-based models. The 
Human bronchial epithelial cell (HBECs) is a key cell type in airway inflammation. Treatment of 
HBECs with inflammatory cytokines, such as IL-1β, TGF-β, TNF-α, and IFN-ϒ, induced miR-
146a expression [149]. miR-146a knockdown and overexpression suggests the miR-146a 
negatively regulates the release of pro-inflammatory cytokines such as IL8 and RANTES [149]. 
These results established the role of a miRNA in the negative feedback regulation of 
inflammation. 
The ASM cell, as discussed earlier, is a cell type that is critical to asthma pathogenesis. In 
asthmatic airways, ASM cells increase in size and number and experience changes in their 
contractile and secretory phenotypes. In human ASM cells, miR-133a controls smooth muscle 20 
 
cell contraction by regulating RhoA, one of the key proteins involved in smooth muscle cell 
contraction [150]. In addition, miR-25 inhibits KLF-4, a potent inhibitor of smooth muscle-
specific gene expression [143]. Although human ASM cells are not the primary cell type 
involved in airway inflammation, cytokines influence their miRNA expression profile. IL-1β 
induces a time dependent increase of mir-146a. However, unlike the previous report that 
inhibition of miR-146a in epithelial cells inhibits cytokine release, mir146a inhibition in ASM 
cells did not regulate IL-8 and RANTES release [141].  This suggests the function of miRNA 
may be highly cell type dependent. Besides inflammatory cytokines, mechanical stretch is also 
known to induce miRNA expression changes. For example, miR-26a is induced by mechanical 
stress and contributes to airway hypertrophy by suppressing glycogen synthase kinase 3β (GSK-
3β), which is an anti-hypertrophic protein [151]. As outlined above, miRNAs play crucial roles 
in controlling airway inflammation and remodeling, both of which are fundamental clinical 
phenotypes of asthma. Therefore, exploring miRNA-based asthma therapy represents novel 
opportunities towards better disease management.  
 
microRNA as biomarkers 
MiRNAs expression patterns are highly regulated and tissue-specific [105]. It is well 
accepted that dysregulation of miRNAs may contribute to a variety of human diseases such as 
cancer, cardiovascular and other chronic diseases [103,106, 152]. Therefore, abnormal miRNA 
signatures in disease states may be valuable diagnostic markers for early disease detection and 
prognosis. The role of miRNA as biomarkers is best studied in the context of cancer [152-154]. 
Aberrant miRNA expression is found to be indicative of tumor progression. Expression levels of 
miRNAs such as Let-7 and miR-155 are correlated with disease survival in non-small cell lung 21 
 
cancer [155, 156]. Circulating miRNAs in blood and other human fluid are very stable under 
most sample storage conditions, making it a convenient biomarker in a clinical setting [157, 158]. 
So far, only a few studies have looked miRNA profiles in asthma and the results are inconsistent. 
One study claims differentially expressed miRNAs in lungs from allergen challenged mice 
compared to controls suggested an important role for miRNA in the pathophysiology of asthma 
[159]. However, another study based on lung biopsies from normal and mild asthmatic patients 
found no significant differences in miRNA expression profiles [160]. Other mouse studies have 
found OVA-induced inflammation caused differential expression in a different set of miRNAs 
[148, 161]. These conflicting results suggest that more mechanistic studies on miRNA’s role in 
lung biology are needed to establish miRNAs as potential biomarkers for asthma. 
 
microRNA as  therapeutics 
  As miRNAs are powerful regulators in a wide variety of diseases settings, there is great 
potential in using miRNAs as therapeutic targets to treat diseases. Currently no FDA approved 
drugs are based on miRNA research, but several promising miRNA targets are under 
development[162-164]. For example, miR-122 is a hepatic specific miRNA critical to hepatitis C 
virus replication. Using anti-sense inhibitors of miR-122 can significantly reduce the replication 
of HCV virus RNA, suggesting that anti-miR-122 can be used as an antiviral therapy [162, 165]. 
Clinical trials using anti-miR-122 are currently ongoing signifying a new era in which anti-miRs 
are used as a novel class of drug. Currently, using miRNAs as therapeutic targets to treat asthma 
is still in its nascent stages as more miRNAs tied to lung biology emerge.  
 
Conclusion  
The wide inter-individual variability in responses to β-agonist and ICS and the lack of 
efficacy of these treatments among severe patients are major problems in the management of 22 
 
asthma symptoms. miRNAs are naturally occurring small evolutionarily conserved endogenous 
molecules that orchestrate and regulate the expression of gene networks. miRNAs rely on base 
pairing to specifically control complex gene regulation networks at single base pair resolution. 
Gene targets of miRNAs are often central among signaling transduction pathways; and therefore, 
miRNAs regulate the regulators and are central players  in cell signaling themselves. miRNA 
profiling combined with mRNA gene expression profiling and protein analysis offers a powerful 
tool for studying global gene regulation networks to greatly enhance our understanding of the 
pathophysiology of asthma. Ultimately, it may answer some fundamental questions about asthma 
such as: what drives airway remodeling and inflammation? Much remains unknown regarding 
the role of miRNAs in lung biology and ASM cell function.  
This thesis aimed to explore the role of miRNA in regulating ASM biology and asthma 
therapy. We have combined the use of various genomic approaches such as next-generation 
sequencing, microarray analysis and cell based functional assays to define the role of miRNAs in 
regulating important ASM phenotypes that have the potential to open up new therapeutic venues 
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Airway smooth muscle (ASM) cells play important physiological roles in the lung, and 
abnormal proliferation of ASM directly contributes to the airway remodeling during 
development of lung diseases such as asthma. MicroRNAs are small yet versatile gene tuners 
that regulate a variety of cellular processes including cell growth and proliferation; however, 
little is known about the precise role of microRNAs in the proliferation of the ASM. Here we 
report that a specific microRNA (miR-10a) controls ASM proliferation through directly 
inhibiting the phosphoinositide 3-kinase (PI3K) pathway. Next-generation sequencing identified 
miR-10a as the most abundant microRNA expressed in primary human airway smooth muscle 
(HASM) cells, accounting for about 25% of all small RNA reads. Overexpression of miR-10a 
reduced mitogen-induced HASM proliferation by ~50%, whereas inhibition of miR-10a 
increased HASM proliferation by ~40%. Microarray profiling of HASM cells expressing miR-
10a mimics identified 52 significantly down-regulated genes as potential targets of miR-10a, 
including the catalytic subunit alpha of PI3 kinase (PIK3CA)—the central component of the 
PI3K pathway. MiR-10a directly suppresses PIK3CA expression by targeting the 3’-UTR of the 
gene. Inhibition of PIK3CA by miR-10a reduced AKT phosphorylation and blunted the 
expression of cyclins and cyclin-dependent kinases that are required for HASM proliferation. 
Together, our study identifies a novel microRNA-mediated regulatory mechanism for PI3K 
signaling and ASM proliferation and further suggests miR-10a as a potential therapeutic target 






Airway smooth muscle (ASM) is the critical effector tissue that maintains bronchomotor 
tone, and phenotypic changes in ASM play a pivotal role in the pathogenesis of a variety of lung 
diseases [1]. Indeed, an increase in ASM tissue mass is a major driver of airway narrowing 
associated with asthma and COPD [2-5]. The pathological change in ASM mass is a combined 
result of hypertrophy (increase in cell size) and hyperplasia (increase in cell number through 
proliferation). ASM cells proliferate in response to a myriad of growth stimuli, including peptide 
growth factors (e.g., PDGF and EGF) as well as bronchoconstrictors (e.g., histamine, thrombin 
and endothelin). These mitogens function by binding to and activating their cognate receptors at 
the surface of ASM cells. For example, PDGF and EGF bind to and activate their respective 
receptor tyrosine kinases (RTKs), whereas bronchoconstrictors mostly act through specific G-
protein coupled receptors (GPCRs).  
Following receptor activation by the mitogens, two main pathways are known to mediate 
the transduction of the proliferation signals in ASM cells: the MAP kinase (MAPK)/ ERK 
pathway and the PI3 kinase (PI3K) pathway. While both are needed for maximal ASM cell 
proliferation [6, 7], these two pathways function mostly independently in ASM cells. Both RTK 
and GPCR mitogens cause robust activation of the MAPK/ERK pathway as measured by ERK 
phosphorylation in ASM cells [8]. Chemical inhibition of ERK phosphorylation reduces 
mitogen-induced DNA synthesis and proliferation in cultured human ASM cells, indicating that 
the pathway is an important regulator of cell proliferation [8-11].  PI3K is the other major 
signaling pathway that regulates ASM proliferation [6, 7, 12, 13]. HASM cells express three 
forms of PI3 kinases: class IA, II and III [12]. RTK and GPCR mitogens both activate class IA 39 
 
PI3K and its signaling [7].  Inhibition of the PI3K signaling prevents mitogen stimulated cyclin 
D1 protein expression and DNA synthesis without affecting ERK signaling [13, 14], whereas 
expression of constitutively active class IA PI3K is sufficient to stimulate DNA synthesis [7]. 
While it is well recognized that MAPK/ERK and PI3K play important roles in regulating ASM 
proliferation, little is known about whether and how these pathways may be regulated in the 
ASM cells.  
MicroRNAs (miRNAs) are small (~22 nucleotides long) non-coding RNAs that mediate 
post-transcriptional gene silencing through binding to the 3’-UTR of target mRNAs to promote 
mRNA degradation and/or translational inhibition [15-17]. MiRNAs play versatile roles in 
normal cell physiology and disease pathogenesis [15]. In the airway, miRNAs have been shown 
to play important roles in regulating inflammation: miR-146 is induced by IL-1β and suppresses 
the activation of NF-κB in alveolar epithelial cells [18], and inhibition of miR-126 suppresses 
inflammation and the development of allergic airway disease [19]. In ASM cells, miRNAs also 
regulate inflammation: several miRNAs (miR-25,-140*,-188,-320) were significantly down-
regulated in human ASM cells that are exposed to inflammatory cytokines such as IL-1β, TNF-α 
and IFN-γ [20], and inhibition of miR-25 up-regulates KLF-4, which is a potent inhibitor of 
smooth muscle-specific gene expression and a mediator of inflammation [20]. MiRNAs also 
regulate the contractility of ASM cells. For example, miR-133a down-regulates RhoA, which is 
involved in regulating mechanical stress and cytoskeleton organization in the ASM [21]; another 
miRNA let-7f targets β2-adrenergic receptor, whose activation causes ASM relaxation [22], 
Relatively little is known about the potential role of miRNAs in the fundamental ASM 
phenotype--proliferation. A very recent study implicated a role for miR-221 in the hyper-
proliferation of ASM cells in severe asthma [23]. However, how miRNAs may regulate the 40 
 
signaling pathways that control ASM proliferation remains largely unknown. In this report, we 
identified a miRNA that is most abundant in ASM as a critical novel regulator of ASM 
proliferation. Functional studies demonstrated that the miRNA regulates ASM proliferation by 
specifically suppressing the PI3K signaling pathway.  
 
MATERIALS AND METHODS 
 
ASM cell culturing and transfection 
Primary HASM cells were isolated from three aborted lung transplant donors with no chronic 
illness. The tissues were obtained from the National Disease Resource Interchange (NDRI) and 
their use approved by the University of Pennsylvania Internal Review Board. HASM cells were 
maintained and cultured in Ham's F12 medium supplemented with 10% fetal calf serum (FCS) 
and antibiotics, as described previously [24, 25]. Passages 4 to 7 HASM cells were used in all 
experiments. MiR-10a mimics and inhibitor (Qiagen) were used to over-express and knockdown 
miR-10a, respectively. Non-targeting scrambled siRNA (Qiagen) was used as a control for miR-
10a mimics experiments; miRNA inhibitor control (Qiagen) was used as a control for miR-10a 
inhibitor experiments. Transfections of miR mimics and inhibitor were performed using the 
DharmaFECT 1 reagent (Thermo Scientific) according to the manufacturer’s protocol.  
 
Construction and sequencing of TrueSeq small RNA libraries 
RNA was extracted with Qiagen miRNeasy kit using the manufacturer’s protocol. RNA 
concentration and quality was measured by Nanodrop (ThermoScientific) and by Bioanalyzer 
(Agilent Technologies 2100), respectively. Truseq Small RNA Sample Preparation kit (Illumina) 41 
 
was used to construct DNA libraries from the RNA preparations (1 μg total RNA per sample) 
according to the manufacturer’s protocol. Briefly, 3’ and 5’ adaptors were sequentially ligated to 
the extracted small RNA species.  Reverse transcriptase PCR amplification was performed in 
which one primer contains a DNA barcode.  The amplified product was then gel purified in order 
to isolate the small RNA library, which is subsequently validated using the Agilent Technologies 
2100 Bioanalyzer.  At this point, three samples (each from one HASM cell line) were pooled 
together (multiplexing) at equal molar concentrations. Quantification of the DNA library samples 
was done by nanodrop or Qubit. Sequence quality and fragment size in the prepared DNA 
libraries were verified by running the samples on a 2% agarose gel. Sequencing (single read, 36 
bp) of the prepared DNA libraries were done using the Illumina Genome Analyzer IIx platform 
at the Boston University Illumina Sequencing Core Facility (Boston, MA). 
 
Analysis of deep sequencing data  
Data cleaning and alignment were performed using the CLC Genomic Workbench (CLCBio). 
Raw sequencing reads with an average length of 36 bp in FASTq format were used for 3’ 
adaptor trimming. Trimmed reads were aligned against the human miRNA database (miRBase 
release 18). MiRNA sequencing count table was generated using the alignment count function of 
the software, which was set to allow two mismatches. Only perfect matched counts were used 
the subsequent analysis. The abundance value for each miRNA was derived using the following 
formula: total percent count for miR-X= (5p mature miRNA reads / total aligned miR reads for 
the sample) ×  100. The percentage of total count reflects the abundance of each miRNA. A pie 
graph was generated for each donor sample to reflect the miRNA composition. For in silico 
analysis of tissue expression patterns of miRNAs,  miRNA enrichment analysis was performed 42 
 
to compare our dataset with published dataset that contains expression data from 170 cell 
line/tissues obtained by small RNAs sequencing [26]. Total percent count from 3 different 
HASM cell lines with total percent count of the published dataset was graphed in R with 
abundance (total percent count) on y-axis and different cell lines on x-axis.  
 
Quantitative RT-PCR of miRNAs and mRNA 
miRNAs and mRNAs were measured using the miScript PCR system with miR-10amiScript 
Primer Assays (Qiagen) on Light cycler 480 (Roche, Indianapolis, IN), following the 
manufacturer’s recommendations. U6 small RNA and beta-actin were used to normalize miRNA 
and mRNA quantification, respectively. Expression values and statistical significance were 
calculated using 2 
-∆∆ Ct method [27, 28].  
 
Microarray-based gene profiling and data analysis 
HASM cells from passage 4 were transfected with either miR-10a mimics or control siRNA. 
About 48 hours post transfection, RNA was extracted from the cells using miRNeasy mini kit 
(Qiagen). Samples were analyzed on the Human Gene 1.0 ST Array (Affymetrix) which contains 
36079 total Refseq transcripts at the Dana-Farber Microarray Core Facility (Boston, MA). Data 
were subsequently processed and analyzed with dChip Software. Transcripts with fold change 
(FC) cut off at 0.8 and 1.25; P<0.05 were identified as significant hits. 
 
ASM proliferation assay 
For H3–thymidine incorporation, HASM cells were serum starved for 24 hours. Cells were 
cultured with radio-labeled H3-thymidine (1μCi/well, PerkinElmer) in the presence and absence 43 
 
of 10% FBS for 24 hours. The cells were then extracted and lysed using a semi-automated PhD 
cell harvester (Cambridge Technology). Radioactivity was counted using a Tri-carb 2910TR 
liquid scintillation counter (Perkin Elmer).To measure cell growth, HASM cells were trypsinized, 
washed two times with PBS and counted with a hemocytometer. 
 
Western blotting 
Cells were lysed in Nonidet P-40 lysis buffer ( 0.5% vol/vol Nonidet P-40, 50 mM Tris-HCL, 
150 mM NaCl) supplemented with protease and phosphatase inhibitors (Roche). Lysates were 
mixed with lithium dodecyl sulfate (LDS) sample buffer and resolved on 4-12% NuPAGE gel 
(Invitrogen) using MOPS running buffer supplemented with Nu-PAGE antioxidant (Invitrogen). 
Proteins were transferred onto a nitrocellulose membrane (GE Amersham) and probed with the 
indicated antibodies. Primary antibodies used in this study include anti-P110α (#4255), anti-
phospho AKT (Ser473) (cat. #4058), anti-AKT (cat. #9272), anti-phospho ERK1/2 (cat. #9101), 
anti-ERK (cat. #4695) (all from Cell Signaling), and anti-GAPDH (GT239) (Gene Tex). 
 
Luciferase reporter assay 
Full length 3’-UTR of PIK3CA was subcloned into a pMir-Target luciferase vector driven by a 
CMV promoter (Origene). Mutant derivatives of the construct were made through site-directed 
mutagenesis using the Quick-change Kit (Stratagene). HEK293 cells were co-transfected with 
the luciferase constructs (wild type or mutant) with miR-10a mimics or control scrambled siRNA 
for 48 hours using Lipofectamine (Invitrogen) at 2:1 molar ratio (miRNA mimics vs. construct 
reporter) ratio following the manufacturer’s protocol. The day before luciferase measurement, 
cells were counted and re-seeded into 96 well assay plate followed by dual-luciferase assay 44 
 
according to manufacturer’s recommended protocol (Promega). Luminescence was measured by 




Small RNA profiling identified miR-10a as the most abundant miRNA in primary human 
ASM cells 
To probe the landscape of microRNA expression in the ASM, we performed next-
generation sequencing of small RNAs in primary human ASM (HASM) cells from 3 healthy 
donors. Small RNAs extracted from the cultured HASM cells were used to construct cDNA 
libraries. Deep sequencing (36 bp single reads) was performed, and sequences were trimmed (to 
remove library adaptors) and aligned against the miRNA database (miRBase). We obtained 
around 4-8 million reads for each of the three HASM cell lines. Up to 70% of the reads were 
aligned to sequences in the miRBase and over 85% of the alignments were perfect matches 
(Table 2-1).  
 
Table 2-1. Summary of sequencing alignments.  
Reads were trimmed and aligned using CLC Genomic Workbench (CLCBio). Trimmed reads 
were aligned against human miRBASE release 18. 
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According to the analyzed deep sequencing data, about 200 miRNAs were detected in 
HASM cells and half of them were relatively well expressed (with > 100 sequencing reads). 
Many of the well-known miRNAs are among the best expressed in HASM cells, including miR-
10a, miR-21, let-7a, miR-100 and miR-26 (Figure 2-1A). Among them, miR-10a is the most 
abundant, accounting for over 20% of all aligned reads (Figure 2-1A). To determine if miR-10a 
is specifically enriched in HASM cells, we performed an in silico miRNA analysis by comparing 
our dataset with a published dataset that contains miRNA deep sequencing data from 170 cell 
lines/tissues [26]. The expression plot showed that miR-10a was expressed at a much higher 
level in HASM cells as compared to all other cells/tissues, whereas a similarly abundant miRNA 
(let-7a) was not differentially expressed in HASM cells (Figure 2-1B). To confirm cellular 
specificity of miR-10a to ASM cells within the lung, we examined miR-10a expression in 
primary airway epithelial cells. The expression of miR-10a in airway epithelial cells was more 
than 30 fold lower than HASM cells (Figure 2-1C). Overall, our data showed that miR-10a is the 
most abundant microRNA in HASM cells and exhibits an ASM-enriched expression. 46 
 
 
Figure 2-1. Next-generation sequencing identified miR-10a as a top highly expressed 
miRNA in ASM cells.  
A) Profiling of miRNA expression in primary human ASM cells using Next-generation deep 
sequencing. RNA was extracted from three primary HASM cell lines and sequenced using next-
generation sequencing (for details, see Materials and Methods section). Pie chart represents the 
distribution of the percentages of total sequencing counts in a representative HASM cell line for 
the top five highly expressed miRNAs. The average percentages for the top five highly expressed 
miRNAs in three HASM cell lines were plotted in the bar graph. B) miR-10a is highly abundant 
in the ASM as compared to other tissues and cell lines. Expression level of miR-10a (as a  47 
 
Figure 2-1. (Continued) 
percentage of total sequencing reads) in HASM cells was compared with that in 170 other cell 
lines / tissues. The red dotted line represents the average percentage of total counts for miR-10a 
in HASM cells; the green line represents the average of miR-10a expression from the other 170 
cell lines/tissues. C) qRT-PCR data comparing the level of miR-10a in HASM cells with that in 
primary airway epithelial cells, RNA was extracted from primary HASM cell lines (3 donors) 
and primary airway epithelial cell lines (2 donors). miR-10a level was measured using qRT-PCR 
(for details, see Material and Methods section) and normalized to U6 small RNA. Standard errors 
are indicated. 
 
Identification of the miR-10a target genes and downstream pathways in ASM cells  
MiRNAs function by suppressing the expression of their target genes [15,16, 29]. To 
identify the genes targeted by miR-10a in HASM cells, we employed an unbiased experimental 
approach (Figure 2-2A). We first transfected HASM cells with miR-10a mimics or a control 
scrambled siRNA. We then determined the effect of miR-10a on the HASM transcriptome by 
whole-genome microarray gene profiling. Differential transcript expression analysis identified 
over 1,000 significant transcript changes in miR-10a mimics-transfected cells as compared to the 
scrambled control (Table 2-2). There are many more down-regulated genes (798) than up-
regulated genes (304) in the mir-10a overexpressed cells. This is expected given the inhibitory 
nature of miRNA regulation on gene expression. The widespread impact of mir-10a on the 
transcriptome is consistent with the notion that a single miRNA regulates expression of many 
genes through both direct and indirect effects [29, 30]. To identify the direct targets of miR-10a, 
we cross-compared our microarray dataset with in silico predicted targets of miR-10a 48 
 
(TargetScan 5.1), which all contain putative sequences that match the seed sequence (2-7 
nucleotides) of the miRNA. Among the 271 predicted miR-10a targets, 248 (~91%) were 
detected in HASM cells by microarray and 52 (~19%) of those putative target genes were 
significantly down-regulated in our microarray dataset (Table 2-3). These 52 genes have a high 
likelihood of being the direct targets of miR-10a, as they contain miR-10a target sites in their 
3’UTR and are down-regulated in miR-10a-transfected HASM cells. Down-regulation of 
selected genes by mir-10a mimic expression in HASM cells was validated by qRT-PCR (Figure 
2- 2B). To identify common biological processes and pathways affected by miR-10a, we 
performed a gene set enrichment analysis on all transcripts that were significantly changed by 
miR-10a mimic transfection. Strikingly, 8 out top 10 enriched pathways affected by miR-10a are 
related to cell cycle (Table 2-4).  
 
Figure 2-2. Microarray profiling identified putative genes and pathways targeted by miR-





Figure  2-2.  (Continued) 
A) A microarray-based approach to identify transcriptomic changes resulted from miR-10a 
mimic expression. HASM cells were transfected with either control scrambled siRNA or miR-
10a mimics for 48 hours. RNAs were then extracted and used for hybridization to Affymatrix-
based Human Gene 1.0 ST microarray with a coverage of 36079 Refseq transcripts (N=2). B) 
qRT-PCR validation of microarray–identified transcript changes. RNA was extracted from 
scrambled siRNA control and miR-10a mimics followed by qRT-PCR for selected down 
regulated miR-10a putative target genes. Genes tested were normalized to beta-actin. Triplicates 
were used for each condition. 
 
Table 2-2. Summary of microarray analysis.  
RNAs from control and miR-10a mimic-transfected HASM cells were analyzed by microarray 
using the Human Gene 1.0 ST Array (Affymetrix) (N=3). Microarray data were subsequently 







Table 2-3. Predicted miR-10a target genes that are down-regulated by miR-10a mimics 
expression in HASM cells.  
Genes with fold change (FC <0.8) and P-value<0.05 were shown. 
Genes  FC  P-value 
CDK6: cyclin-dependent kinase 6  0.37  0.00 
USP46: ubiquitin specific peptidase 46  0.39  0.00 
RAP2A: RAP2A, member of RAS oncogene family  0.40  0.02 
ITGB8: integrin, beta 8  0.40  0.01 
CBX5: chromobox homolog 5 (HP1 alpha homolog, Drosophila)  0.41  0.01 
H3F3B: H3 histone, family 3B (H3.3B)  0.43  0.00 
ST6GALNAC6: ST6 -N-acetylgalactosaminide alpha-2,6-sialyltransferase 6  0.43  0.00 
CRLF3: cytokine receptor-like factor 3  0.48  0.02 
TMEM183A: transmembrane protein 183A  0.52  0.00 
TMEM183B: transmembrane protein 183B  0.52  0.00 
LANCL1: LanC lantibiotic synthetase component C-like 1 (bacterial)  0.54  0.01 
ANXA7: annexin A7  0.55  0.01 
CYTH1: cytohesin 1  0.57  0.00 
ARNTL: aryl hydrocarbon receptor nuclear translocator-like  0.58  0.02 
ZMYND11: zinc finger, MYND domain containing 11  0.60  0.00 
BDNF: brain-derived neurotrophic factor  0.61  0.01 
E2F7: E2F transcription factor 7  0.63  0.01 
UBE2I: ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)  0.63  0.01 
CNOT6: CCR4-NOT transcription complex, subunit 6  0.63  0.01 
KLHDC10: kelch domain containing 10  0.64  0.01 
GATA6: GATA binding protein 6  0.65  0.01 
GOLGA3: golgi autoantigen, golgin subfamily a, 3  0.65  0.00 
SMAP1: stromal membrane-associated GTPase-activating protein 1  0.66  0.01 
MAPRE1: microtubule-associated protein, RP/EB family, member 1  0.66  0.03 
TFAP2C: transcription factor AP-2 gamma (activating enhancer binding 
protein 2 gamma)  0.67  0.02 
NCOR2: nuclear receptor co-repressor 2  0.68  0.04 
MAP3K7: mitogen-activated protein kinase kinase kinase 7  0.68  0.03 
HSPC159: galectin-related protein  0.68  0.03 
FNBP1L: formin binding protein 1-like  0.70  0.03 
PAPD5: PAP associated domain containing 5  0.70  0.04 
PIK3CA: phosphoinositide-3-kinase, catalytic, alpha polypeptide  0.71  0.00 
SCARB2: scavenger receptor class B, member 2  0.72  0.04 
CNNM4: cyclin M4  0.72  0.00 
TET2: tet oncogene family member 2  0.72  0.04 51 
 
Table 2-3. (Continued) 
SLC30A4: solute carrier family 30 (zinc transporter), member 4  0.73  0.02 
AP4E1: adaptor-related protein complex 4, epsilon 1 subunit  0.73  0.01 
ARSJ: arylsulfatase family, member J  0.74  0.01 
MTMR3: myotubularin related protein 3  0.75  0.03 
JARID2: jumonji, AT rich interactive domain 2  0.75  0.04 
MAPKBP1: mitogen-activated protein kinase binding protein 1  0.76  0.03 
RORA: RAR-related orphan receptor A  0.76  0.01 
BRWD3: bromodomain and WD repeat domain containing 3  0.76  0.03 
CREB1: cAMP responsive element binding protein 1  0.77  0.01 
SMURF1: SMAD specific E3 ubiquitin protein ligase 1  0.77  0.00 
MAP3K2: mitogen-activated protein kinase kinase kinase 2  0.78  0.01 
RPRD1A: regulation of nuclear pre-mRNA domain containing 1A  0.78  0.04 
BAZ2B: bromodomain adjacent to zinc finger domain, 2B  0.78  0.04 
USP25: ubiquitin specific peptidase 25  0.79  0.01 
NUP50: nucleoporin 50kDa  0.79  0.02 
MTF1: metal-regulatory transcription factor 1  0.79  0.03 
WWC2: WW and C2 domain containing 2  0.80  0.02 














Table 2-4. Top 10 enriched pathways regulated by miR-10a 
All significant transcriptome changes (FC<0.8 or FC>1.25, P-value<0.05) were included in the 
gene-set enrichment analysis using the GeneGo software. The table lists enriched pathways with 
P-values and FDR (false discovery rate) q-values adjusted for multiple comparisons. 
 
Rank  Pathways  P-value  FDR 
1  Cell cycle_The metaphase checkpoint   3.651E-20  2.140E-17 
2  Cell cycle_Chromosome condensation in prometaphase   1.054E-19  3.089E-17 
3  Cell cycle_Role of APC in cell cycle regulation   2.150E-18  4.200E-16 
4  Cell cycle_Initiation of mitosis  5.129E-13  7.514E-11 
5  Cell cycle_Start of DNA replication in early S phase   4.915E-10  5.534E-08 
6 
DNA damage_ATM / ATR regulation of G2 / M 
checkpoint   5.666E-10  5.534E-08 
7  DNA damage_ATM/ATR regulation of G1/S checkpoint   1.076E-07  9.012E-06 
8  Cell cycle_Spindle assembly and chromosome separation   1.495E-07  1.095E-05 
9  Cell cycle_Cell cycle (generic schema)   3.672E-07  2.391E-05 
10  Cell cycle_Role of 14-3-3 proteins in cell cycle regulation   5.590E-07  3.276E-05 
 
 
miR-10a inhibits HASM cell proliferation 
Because our pathway analysis suggests that miR-10a may function in cell cycle 
regulation, we next examined the effect of miR-10a on HASM cell growth and proliferation. We 
assessed HASM cell proliferation by two independent methods: cell counting and thymidine 
incorporation, which directly measures the rate of DNA synthesis. While the number of control 
HASM cells (transfected with scrambled siRNA) increased by 3 fold during 72 hours post serum 
stimulation, the number of miR-10a mimics transfected-HASM cells only increased by 2 fold 
during the same time period. Such a reduction in cell number in miR-10a mimics-transfected 
cells was also evident at baseline only 1 day after transfection (Figure 2-3A). Consistent with the 
result observed on direct cell counting, mir-10a mimics-transfection in HASM cells reduced 53 
 
FBS-induced thymidine incorporation by ~50% as compared to the control-transfected cells 
(Figure 2-3B). Conversely, transfection of an inhibitor of miR-10a increased thymidine uptake 
by ~70% in HASM cells (Figure 2-3C).  Together, these results demonstrated that miR-10a is a 
negative regulator of ASM proliferation.  
 
Figure 2-3. Effects of miR-10a on ASM proliferation.  
A) miR-10a mimic expression inhibits HASM proliferation. HASM cells were transfected with 
either scrambled siRNA or miR-10a mimics followed by serum starvation for 24 hours. Cells 
were then allowed to grow in the presence of FBS for additional 24 or 72 hours, after which cell 
numbers were counted. Triplicates were done for each condition. Error bars represent standard 
errors. *, P<0.05. B) miR-10a mimics inhibit DNA synthesis in HASM cells. HASM Cells were 
transfected for 48 hours with either scrambled siRNA or miR-10a mimics and then serum-
starved for 24 hours. H3-thymidine incorporation was measured in cells after 24 hours of FBS 
stimulation. Error bars represent standard error (N=5). **, P<0.01. C) miR-10a inhibitor  
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Figure 2-3. (Continued).  
increases DNA synthesis in HASM cells. HASM cells were transfected with either a control miR 
inhibitor or miR-10a inhibitor for 48 hours, and serum starved for 24 hours. H3-thymidine 
incorporation was measured in cells after 24 hours of FBS stimulation. Error bars represent 
standard error (N=5).  **, P<0.01. All comparisons were performed using two-tailed student’s 
test. 
 
miR-10a reduces the expression of cdks and cyclins in HASM cells 
ASM cell proliferation is directly controlled by cyclins and cyclin-dependent kinases 
(cdks) (32, 33). To further investigate the effect of miR-10a on HASM proliferation, we 
examined the expression of several selected cdks and cyclins (Cdk2, Cdk6, Cdc6, cyclin A2, 
cyclin B1 and cyclin B2), all of which are known to play important roles in cell cycle control: 
Cdk2 and cdk6 regulate the check point of G1 to S phase [31, 32]. Cdc6 initiates DNA synthesis 
in the S phase and its activity is tightly regulated by Cyclin A and Cdk2 [33, 34]. Cyclins B1 and 
B2 regulate G2 to M phase transition [35]. As shown in Figure 2-4A, mRNA levels as measured 
by qRT-PCR for all of the examined cdks and cyclins were decreased (ranging from 40-70% 
reduction) in mir-10a mimics-transfected HASM cells. Although down-regulated by miR-10a 
overexpression, none of these genes except cdk6 was predicted to be direct target of mir-10a, 
suggesting that miR-10a likely acts directly on genes that are in the pathways upstream of 






MiR-10a inhibits PI3K signaling pathway in the HASM cells 
Two major signaling pathways (PI3K-AKT and MAPK/ERK) transduce proliferation 
signals leading to the activation of cyclins and cdks in HASM cells (8-13). Upon growth factor 
stimulation, PI3K is activated and increases the production of PIP3, which activates PDK1 and 
causes downstream phosphorylation of AKT [12]; activation of MAPK/ERK pathway leads to 
the phosphorylation of the kinase. To determine which pathway is regulated by miR-10a, we 
determined the effect of miR-10a on PI3K and MAPK/ERK signaling pathway by measuring the 
phosphorylation of AKT and ERK. As shown in Figure 2-4B, EGF treatment activated AKT 
phosphorylation in both control and miR-10a mimic-transfected HASM cells. However, the 
extent of activation as indicated by the intensity of pAKT signal was reduced by ~55% in miR-
10a mimics-transfected cells. Similarly, the level of AKT phosphorylation induced by FBS was 
reduced by ~34% in miR-10a overexpression HASM cells (Figure 2-4C). In contract, we did not 
observe a consistent significant effect of miR-10a on ERK phosphorylation (Figure 2-4C). These 
results suggest that the inhibitory effect of mir-10a on HASM cell proliferation is mostly 







Figure 2-4. Effects of miR-10a on cyclin expression and AKT/ERK phosphorylation.  
A) miR-10 mimic expression inhibits the expression of multiple cyclins and Cdks. HASM cells 
were transfected with scrambled siRNA control or miR-10a mimics for 48 hours, RNA was 
extracted and analyzed with qRT-PCR to examine the level of different cyclins and Cdks gene 
expression. Triplicates were used for each condition.  B-C) miR-10a mimic expression inhibits. 
PI3K-Akt signaling. HASM cells transfected with scrambled siRNA control or miR-10a mimics 
for 48 hours were first serum starved for 24 hours and then stimulated for 10 min with 50ng/ml 
EGF or 10% FBS. Lysates from the cells were used to determine the level of AKT and ERK 
phosphorylation by immunoblotting. Total AKT and ERK levels as well as GAPDH were also 
determined by immunoblotting using indicated antibodies. 
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PIK3CA is a direct gene target of miR-10a  
We next determined which gene(s) in the PI3K-AKT pathway is the direct miR-10a 
target that mediates the function of the miRNA. In our microarray experiment and the 
subsequent qRT-PRC validation (Figure 2- 2B), we found that the PIK3CA gene, which encodes 
the catalytic subunit of class IA form of PI3K, was significantly down-regulated (>60%) 
following miR-10a mimics expression in HASM cells. To further examine the effect of miR-10a 
on PIK3CA expression, we re-examined the effect of miR-10a mimics on PIK3CA mRNA along 
with miR-10a inhibitors. Our result showed that miR-10a mimic expression led to significant 
down-regulation in PIK3CA mRNA, whereas miR-10a inhibitors caused a modest increase in 
PI3K mRNA expression (Figure 2-5A). We next used Western blotting to detect PIK3CA protein 
expression following miR-10a mimic and inhibitor transfection in HASM cells. As shown in 
Figure 2-5B, miR-10a mimics reduced PIK3CA protein expression by ~60%, whereas miR-10a 
inhibitor increased PIK3CA protein expression by ~2 fold. These results clearly demonstrated 
the inhibitory effect of miR-10a on PIK3CA expression. PIK3CA was predicted in silico to be a 
miR-10a target gene, as the 3’-untranslated region (3’-UTR) of the transcript contains a site that 
is complementary to the seed sequence of miR-10a. To determine if miR-10a suppresses 
PIK3CA expression by direct targeting of the 3’UTR of PIK3CA, we used a luciferase reporter-
based assay. We fused either the wild type or a mutant form (in which we mutated the putative 
miR-10a target sequence through site directed mutagenesis) of the PIK3CA 3’-UTR to the 
luciferase gene under the control of a CMV promoter. We then co-transfected the luciferase 
construct (wild type or mutant) along with either miR-10a mimics or control small RNA into 
HEK293 cells and measured the luciferase activity. As shown in Figure 2-5C, miR-10a mimic 
significantly reduced (by ~40%) the luciferase activity of the wild type 3’-UTR construct. 58 
 
However, this repression of luciferase activity by miR-10a mimics was abolished in cells 
expressing the mutant 3’-UTR of PIK3CA with changes of two nucleotides in the miR-10a 
binding site (Figure 2-5C), indicating that the site in the PIK3CA 3’-UTR is required for the 
inhibitory effect of miR-10a. Together, these data demonstrated that miR-10a directly inhibits 
PIK3CA expression. 
 
Figure 2-5. Effects of miR-10a on PIK3CA expression.  
 
A) Effects of miR-10a mimics and inhibitor on PIK3CA mRNA expression. RNA was extracted 
from HASM cells transfected with scrambled siRNA control, miR-10a mimics, control miR-




Figure 2-5.  (Continued) 
between miR-10 and its control-transfected HASM cells (or between miR-10a inhibitor and its 
control). Error bars represent standard error (N=3), *, p<0.05. B) Effects of miR-10a mimics and 
inhibitor on PIK3CA protein expression. HASM cells were transfected with scrambled small 
RNA control, miR-10a mimics, control miR-inhibitor, or miR-10a inhibitor.  PIK3CA protein in 
the transfected HASM cells was detected using immunoblotting. The blots were scanned and  
PIK3CA protein bands were quantified using the NIH ImageJ software and normalized against 
GAPDH. Error bars represent standard error (N=3), *, P<0.05. C) miR-10a directly targets the 
3’-UTR of the PIK3CA gene. Luciferase construct was used to test if miR-10a directly binds to 
PIK3CA. Full length 3’UTR of PIK3CA was subcloned into the CMV-driven pMir-Target 
luciferase vector (Origene). A mutant derivative (with two site mutation in the putative miR-10a 
recognition site) of the construct were made through site-directed mutagenesis.HEK293 cells 
were co-transfected with the luciferase construct with either miR-10a mimics and control 
scrambled small RNA for 48 hours, followed by dual-luciferase assays. Error bars represent 
standard error (N=10), *, p<0.05, **, p<0.01. All statistical comparisons were calculated using 
two tailed student’s t-test. D) A model for miR-10a-mediated inhibition on PI3K signaling and 
ASM proliferation.  PI3K mediates the proliferation signals from mitogen-activated RTKs and 
GPCRs in the ASM. MiR-10a directly inhibits the expression of PIK3CA—the central 








Dysregulated ASM proliferation is a major driver of airway narrowing associated with 
lung diseases such as asthma. As such, a better understanding of how ASM proliferation is 
regulated will advance our understanding of lung diseases and may provide mechanistic insights 
for improving asthma therapy. Using the Next-generation deep sequencing, we identified a 
highly abundant miRNA (miR-10a) in cultured primary human ASM cells. We demonstrated 
that miR-10a inhibits the DNA synthesis and proliferation of ASM cells. 
Mechanistically, miR-10a modulates ASM proliferation by directly targeting PIK3CA and the 
associated PI3K pathway. These findings reported here thus revealed a novel miRNA-based 
mechanism for regulating ASM proliferation (Figure 2-5D). To our knowledge, this study is also 
the first to experimentally identify a specific miRNA as a regulator of PIK3CA-the central 
component of the PI3K signaling pathway.  
We initially focused on miR-10a largely because of its extreme abundance in ASM cells. 
While miR-10a is ubiquitously expressed, its expression in ASM is much higher than that in all 
other tissues including airway epithelial cells. A recent study globally examined miRNA 
function found that 60% of all miRNAs expressed at relatively low levels exert little effect on 
gene expression and are thus essentially non-functional [36], suggesting that only miRNAs that 
are highly abundant can mediate consequential target gene suppression. Moreover, miRNAs 
exhibiting tissue/cell-enriched expression pattern often play important roles in that tissue or cell 
type. For example, miR-1a, which is highly enriched and abundant in the heart, regulates cardiac 
remodeling [26, 37]; miR-122a, which accounts for 78% of all miRNAs in the liver, controls 
multiple processes critical for hepatic function [38]. Consistent with these studies, our study 61 
 
demonstrated that the highly abundant miR-10a impacts an important ASM phenotype by 
inhibiting DNA synthesis and proliferation of ASM cells.  
MiR-10a is transcribed from the Hoxb locus. Several other miRNAs with similar 
sequences (miR-10b, miR-99a/b and miR-100) are also transcribed from the vicinity of this Hox 
locus. Interestingly, miR-100 is also among the top five highly expressed miRNAs identified. 
The Hoxb locus is involved in lung branching morphogenesis and may determine cell fate in the 
lung [39]. In mouse smooth muscle cells, miR-10a is induced by retinoic acid to promote the 
differentiation of embryonic stem cell into smooth muscle cells [40]. It is conceivable that miR-
10a expression increases during smooth muscle development and remains high post 
differentiation to control the growth of smooth muscle cells. 
Previous studies had clearly demonstrated the role of the PI3K pathway in HASM cell 
proliferation [6, 7, 13]. Our identification of miR-10a as a direct regulator of PI3K provides an 
additional layer of regulation in ASM proliferation. We established miR-10a as a novel regulator 
of PI3K signaling and demonstrated that miR-10a inhibits HASM cell proliferation by 
suppressing PI3K signaling through direct binding to the 3’-UTR of PIK3CA. Interestingly, we 
note that PIK3CA may not be the only miR-10a target in the PI3K pathway. The cyclin-
dependent kinase Cdk6, which is known to regulate cell proliferation through the regulation of 
cell cycle [32] is also one of the top down-regulated miR-10a target genes. It is possible that 
miR-10a targets both PIK3CA and Cdk6 to inhibit PI3K signaling (Fig. 5D). At present we 
cannot exclude the possibility that the observed miR-10a inhibitory effect on ASM proliferation 
is a combination of inhibition on both PIK3CA and Cdk6. Future experiments aiming to 
determine the direct targeting of Cdk6 by miR-10a may help strengthen the functional role of 
miR-10a in regulating the PI3K signaling pathway and ASM proliferation. 62 
 
PI3K signaling is not the only pathway known to regulate ASM proliferation. Both 
PI3K/AKT and MAPK/ERK pathways are involved in growth factor-stimulated ASM 
proliferation [7, 9-11, 13]. Consistent with these studies, our data showed that, upon mitogen 
stimulation, there is a robust increase in AKT and ERK phosphorylation. Our microarray 
analysis of miR-10a-transfected HASM cells also showed that multiple genes (MAP3K2, 
MAP3K7 and MAPBP1) in the MAPK/ERK signaling pathway were down-regulated following 
miR-10a expression. Because of these results, we also examined the effect of miR-10a mimics 
on ERK phosphorylation. Despite the fact that multiple genes along the MAPK signaling 
pathway were down-regulated, miR-10a does not seem to significantly affect MAPK signaling as 
indicated by ERK phosphorylation. It is possible that the MAP3Ks are several steps upstream of 
the MAPK signaling pathway and other MAPKKKs may have compensated for the effect of the 
down-regulation of MAP3K2 and MAP3K7 by miR-10a.    
Both MiR-10a and PI3K are highly evolutionarily conserved and are ubiquitously 
expressed in many other types of cells. We predict that the miR-10a regulation of PI3K play 
important biological roles in tissues other than ASM proliferation. Indeed, miR-10a has been 
implicated in multiple cellular processes, such as inflammation, cell differentiation, immune cell 
function, and tumorigenesis [40-48]. In particular, miR-10a has been implicated in development 
and cancer, as its expression is frequently altered in several cancers [49] and changes during 
cancer progression [50-52]. The generation of miR-10a knockdown transgenic mice revealed that 
miR-10a deficiency increases the frequency of intestine carcinoma [50]. This is highly relevant 
given that PI3K is one of the most dysregulated signaling pathways in cancer [53]. It is possible 
that alteration in miR-10a expression may contribute to abnormal PI3K signaling in cancer. 63 
 
Exploring the miR-10a-PI3K link further will extend our current ASM study and may yield 
important mechanistic insights into cancer cell proliferation. 
In summary, our study established miR-10a as a novel regulator of PI3K signaling and 
demonstrated that miR-10a inhibits ASM cell proliferation by suppressing PI3K signaling 
through direct targeting of the central PI3K pathway component (PIK3CA). Our findings raise 
the possibility of using miR-10a as a novel therapeutic agent to suppress PI3K signaling in order 
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Asthma is a chronic respiratory disease characterized by airway hyper-responsiveness 
and chronic lung inflammation. The mainstay therapies for asthma are β-2 adrenergic receptor 
agonists, which dilate the airway; and corticosteroids, which suppress inflammation. A major 
limitation associated with these therapies is the widely observed inter-individual variability in 
drug response. Hence, asthma pharmacogenetics has been an active field examining the 
association between single nucleotide polymorphisms (SNPs) in the genome and variability in 
treatment response. However, pharmacogenetic predictions of response to β-agonist and 
corticosteroid treatments remain unworkable with current genetic variants explaining too little of 
the overall variation. MicroRNAs (miRNA) are small yet versatile gene tuners that add an 
additional level of post transcriptional regulation. They are known to play important roles in 
regulating cellular processes such as cell proliferation and inflammation, which are fundamental 
biological processes that affect asthma pathogenesis. While miRNAs have been associated with 
some drug responses, they have not been implicated in asthma therapy. Therefore, we 
hypothesized that miRNAs are novel asthma drug responsive genetic elements, and they can be 
combined with future pharmacogenetics studies to better predict asthma treatment response.  We 
used next-generation small RNA sequencing to identify β-agonist and corticosteroid responsive 
miRNAs. In this study, we examined the effect of albuterol (a β-agonist), dexamethasone (a 
corticosteroid) and combined treatment (albuterol plus dexamethasone) on the miRNA 
expression profiles of human airway smooth muscle cells (HASM) from three different donors. 
We identified around 200 miRNAs in HASM cells among the three donors with similar baseline 
expression profiles. Surprisingly, we did not detect significant differential expression of miRNAs 70 
 
under the treatment conditions examined. To test if the treatment conditions were sufficient to 
induce genome wide transcriptional changes, we found that IL-8, IL-6 and RGS5, genes 
previously reported to be altered by albuterol, were changed in the same samples.  Notably, 
however, donor to donor variation was high. We also tested several GR responsive genes 
discovered from a parallel RNA sequencing study looking at the transcriptome effects of 
dexamethasone conducted by our group and collaborators. CRISPLD2, PTX3, SERPINA3 were 
induced by ~2-10 fold upon 1μM dexamethasone treatment, whereas KCTD12 which is known 
to contain a negative GRE in its promoter was suppressed by ~80%. In conclusion, our results 
suggest that albuterol and dexamethasone do not regulate miRNA levels under conditions that 

















Asthma is a chronic respiratory disease that affects over 300 million people world-wide. 
It is characterized by airway inflammation, remodeling and hyper-responsiveness [1-3]. 
Continuous research efforts have offered great insights linking the clinical features of asthma 
with genetics and novel biological pathways underlying the disease [2]. Based on the molecular 
understanding of the disease, two mainstay treatments were developed: β2-adrenergic receptor 
agonists, which promote airway relaxation; and corticosteroids, which have profound anti-
inflammatory effects. β2-adrenergic receptor agonists are potent bronchodilators that induce 
cyclic adenosine monophosphate (cAMP) to mediate smooth muscle relaxation [4].  
Glucocorticoids exert their anti-inflammatory effect through the activation of glucocorticoid 
receptors (GRs). Once activated, GRs translocate to the nucleus to bind directly to DNA to 
modulate transcription or bind to NF-kB to attenuate NF-kB-mediated inflammatory gene 
transcription [5].  
These treatments were developed a decade ago and have modest efficacy overall, which 
is mainly due to the widely observed inter-individual variability in drug response. Hence, asthma 
pharmacogenomics has been an active area of research in order to develop methods to effectively 
predict an individual’s response to different asthma treatments [6-9]. In the past, the bulk of 
pharmacogenomics studies have focused on understanding the role of single nucleotide 
polymorphisms (SNPs) in the genome and mRNA expression level variation. These biomarkers 
are tested for association with clinical phenotypes such as lung function measurements. In recent 
years, the discovery of  microRNAs (miRNA) furthered our understanding of gene regulation 72 
 
and opened up a new area of interest to investigate miRNAs as important genetic elements in 
predicting drug response [10, 11]. 
miRNAs are small 22-nucleotide long RNA molecules that suppress target gene 
expression post-transcriptionally. miRNAs function by binding directly to the target’s 3’UTR 
[12-14]. Recent studies have shown that the variations in miRNA expression translate into 
expression differences of genes that play crucial roles in determining drug responses. This is best 
demonstrated in cancer therapy where the expression levels of multiple miRNAs are altered by 
cancer treatments; and these miRNAs, in turn, regulate drug response. Consequently, changes in 
miRNA expression caused by drug treatment may induce acquired drug resistance [15-17]. 
miRNAs play versatile roles in normal cell physiology and disease pathogenesis [13]. In 
the airway, miRNAs play important roles in regulating inflammation: miR-146 is induced by IL-
1β and suppresses NF-κB activation in alveolar epithelial cells [18]; and inhibition of miR-126 
suppresses inflammation and the development of allergic airway disease [19]. In ASM cells, 
miRNAs also regulate inflammation: several miRNAs (miR-25,-140*,-188,-320) were 
significantly down-regulated in human ASM cells exposed to inflammatory cytokines such as 
IL-1β, TNF-α and IFN-γ [20]; inhibition of miR-25 up-regulates KLF-4, which is a potent 
inhibitor of smooth muscle-specific gene expression and a mediator of inflammation [20]. 
miRNAs also regulate the contractility of ASM cells. For example, miR-133a down-regulates 
RhoA, which is involved in regulating mechanical stress and cytoskeleton organization in the 
ASM [21]. Notably, microRNA let-7f inhibits β2-adrenergic receptor, whose activation causes 
ASM relaxation [22], 
Our study employed a synergistic approach by tying together basic miRNA biology and 
pharmacogenetics to examine the effects of common asthma treatments – β-agonists and 73 
 
glucocorticoids – on the miRNA expression landscape in order to identify novel drug responsive 
miRNAs. These drug responsive miRNAs can be used in future association and mechanistic 
studies to unravel the role of miRNAs in the regulation of β-agonist and corticosteroid responses. 
Recent advances in sequencing technologies have made it possible to perform a 
quantitative and comprehensive survey of small RNAs using next-generation sequencing [23]. 
Next-generation sequencing utilizes massive cDNA sequencing for direct measuring counts of 
different small RNA species in a given sample. This new technology offers several advantages 
over the array based approaches: 1) the detection of small RNA is not limited to the probes 
printed on the array; 2) unlike the hybridization-based approach, direct sequencing offers single 
base pair resolution and thus accurate profiling miRNA variants. 3) Lastly, RNA sequencing 
offers a wider detection range: transcripts highly and lowly expressed are accurately identified 
[23, 24]. 
We used next-generation small RNA sequencing to examine the effect of albuterol (a β-
agonist), dexamethasone (a corticosteroid) and combined treatment (albuterol plus 
dexamethasone) on the miRNA expression profiles of human airway smooth muscle cells 
(HASM) from three different donor cell lines. We identified around 200 miRNAs in HASM cells 
that have comparable baseline expression pattern among the three donors. Surprisingly, we did 
not detect significant differential expression of miRNAs under treatment conditions of 1μM 
albuterol, 1μM dexamethasone and combined treatment after 18 hours. To test for if the 
treatment conditions were sufficient to induce transcriptional changes, we found that IL-8, IL-6 
and RGS5, genes that were previously reported to be altered by albuterol, were changed, 
although the donor to donor variation was high. We also tested several GR responsive genes 
discovered in a parallel RNA sequencing study looking at the poly-adenylated transcriptomic 74 
 
effect of dexamethasone, which was conducted by our group and collaborators. CRISPLD2, 
PTX3, SERPINA3 were induced by ~2-10 fold upon 1μM dexamethasone treatment, whereas 
KCTD12 which is known to contain a negative GRE in its promoter was suppressed by ~80%. In 
conclusion, our result suggests that albuterol and dexamethasone do not regulate miRNA 
expression under conditions that are sufficient to induce large mRNA expression changes.  
 
 
MATERIALS AND METHODS 
 
HASM cell culture and drug treatment 
Primary HASM cells were isolated from three aborted lung transplant donors with no chronic 
illness. The tissues were obtained from the National Disease Resource Interchange (NDRI) and 
their use was approved by the University of Pennsylvania Internal Review Board. HASM cells 
were maintained and cultured in Ham's F12 medium supplemented with 10% fetal calf serum 
(FCS) and antibiotics, as described previously [25, 26]. Passages 4 to 7 HASM cells were used in 
all experiments. HASM cells were treated with 1μM albuterol, 1μM dexamethasone and 1μM 
albuterol in combination with 1μM dexamethasone for 18 hours with corresponding DMSO 
controls. 
 
Construction and sequencing of TrueSeq small RNA libraries 
RNA was extracted with the Qiagen miRNeasy kit using the manufacturer’s protocol. RNA 
concentration and quality was measured by Nanodrop (ThermoScientific) and by Bioanalyzer 
(Agilent Technologies 2100), respectively. The Truseq Small RNA Sample Preparation kit 75 
 
(Illumina) was used to construct DNA libraries from the RNA preparations (1 μg total RNA per 
sample) according to the manufacturer’s protocol. Briefly, 3’ and 5’ adaptors were sequentially 
ligated to the extracted small RNA species.  Reverse transcriptase PCR amplification was 
performed in which one primer contains a DNA barcode.  The amplified product was then gel 
purified in order to isolate the small RNA library. The library is size-validated using the Agilent 
Technologies 2100 Bioanalyzer.  Three donor cell lines under each condition were pooled 
together (multiplexing) at equal molar concentrations. Quantification of the DNA library samples 
was performed by nanodrop (ThermoFisher) or Qubit (Life Technologies). Sequence quality and 
fragment size in the prepared DNA libraries were verified by running the samples on a 2% 
agarose gel. Sequencing (single read, 36 bp) of the prepared DNA libraries was done using the 
Illumina Genome Analyzer IIx platform at the Boston University Illumina Sequencing Core 
Facility (Boston, MA). 
 
Analysis of deep sequencing data  
Data cleaning and alignment were performed using the CLC Genomic Workbench (CLCBio). 
Raw sequencing reads with an average length of 36 bp in FASTq format were used for 3’ 
adaptor trimming. Trimmed reads were aligned against the human miRNA database (miRBase 
release 18). miRNA sequencing count tables were generated using the alignment count function 
of the software, which was set to allow two mismatches. Only perfectly matched counts were 
used in the subsequent analysis. miRNA differential expression analysis was performed using 
DESeq in R (Bioconductor) [27]. Data were fitted against the negative binomial distribution for 
differential analysis [27]. 
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Quantitative RT-PCR of miRNAs and mRNA 
miRNAs and mRNAs were measured using the miScript PCR system with miR-10a miScript 
Primer Assays (Qiagen) on Light cycler 480 (Roche, Indianapolis, IN), following the 
manufacturer’s recommendations. U6 small RNA and beta-actin were used to normalize miRNA 
and mRNA quantification, respectively. Expression values and statistical significance were 
calculated using 2 





Treatment of albuterol, dexamethasone or combination of the two drugs did not induce 
significant changes in miRNA expression in HASM cells 
To identify β-agonist and corticosteroid responsive miRNAs, we performed next-
generation small RNA sequencing on HASM cells treated with 1μM albuterol, 1μM 
dexamethasone and 1μM albuterol/dexamethasone combined. We obtained around 4-10 million 
reads from all samples and ~50-90% of reads aligned to miRbase release 18. About 90% of all 
aligned reads were perfect matches. We performed differential expression analysis using DESeq, 
which is a statistical package that detects differential expression using RNA sequencing count 
data [27]. Under the conditions of 1µ M albuterol, dexamethasone and combined treatment for 18 
hours, we did not detect any significant changes between control and the three treatment groups 
adjusted at a 10% false discovery rate (FDR) (Figure 3-1 to Figure3-3). 77 
 
 
Figure 3-1. Effects of 1µM albuterol on miRNA expression in primary HASM cells.  
HASM cells from three donors were treated with 1µM albuterol. Small RNAs were sequenced 
using Genome Analyzer II and differential expression analysis was performed using DESeq. 
Each black dot represents an individual miRNA. Log2 fold change was calculated based on the 
normalized sequencing count between control and albuterol treated samples. –Log (P value) was 
calculated using raw p-values.  Most of relative changes in miRNA expression were within two 
fold and none of these changes reached statistical significance.   78 
 
 
Figure 3-2. Effects of 1µM dexamethasone on miRNA expression in primary HASM cells.  
HASM cells from three donors were treated with 1µM dexamethasone. Small RNAs were 
sequenced using Genome Analyzer II and differential expression analysis was performed using 
DESeq. Each black dot represents an individual miRNA. Log2 fold change was calculated based 
on the normalized sequencing count between control and albuterol treated samples. –Log (P 
value) was calculated using raw p-values.  Most of relative changes in miRNA expression were 
within two fold and none of these changes reached statistical significance. 79 
 
 
Figure 3-3. Effects of 1µM dexamethasone plus albuterol on miRNA expression in primary 
HASM cells.  
HASM cells from three donors were treated with 1µM dexamethasone and albuterol. Small 
RNAs were sequenced using Genome Analyzer II and differential expression analysis was 
performed using DESeq. Each black dot represents an individual miRNA. Log2 fold change was 
calculated based on the normalized sequencing count between control and albuterol treated 
samples. –Log (P value) was calculated using raw p-values.  Most of relative changes in miRNA 
expression were within two fold and none of these changes reached statistical significance. 
 
As shown in Figure 3-1 to Figure 3-3, under all three treatment conditions, most of the 
changes in miRNA expression are within 2 fold and none of these changes even reached an 80 
 
uncorrected threshold of p<0.05 before adjusting for multiple comparison at 10% FDR. After we 
adjusted for 10% FDR, as expected, none of these changes reached statistical significance.  To 
explore what might have contributed to the insignificant miRNA expression fluctuations, we 
graphed sequencing counts versus fold change for each miRNA (data not shown) and found that 
most of the changes in miRNA expression occurred at low sequencing counts. In this range, 
changes are more prone to variation by chance suggesting that the changes were random and 
most likely were due to error introduced by sequencing count normalization. 
We considered the possibility that our experimental design may not offer enough power 
to detect subtle changes that are around 2-fold given the variations between individual donor cell 
lines. Therefore, for each condition and donor, we manually set a cut off at 2 fold in both 
directions (up and down) and selected the miRNAs that were changed more than 2 fold (data not 
shown). After applying these selection criteria, we realized that none of the changes were 
consistent among the three donor cell lines; therefore, for downstream validation experiments we 
selected miRNAs that are changed more than 2 fold in 2 out of the 3 donor cell lines. 
Interestingly, after we applied the new selection criteria, only samples treated with albuterol had 




















We then performed qRT-PCR on the consistently changed miRNAs (miR-99, miR-199, 
and miR-191) to validate their changes (Figure 3-4). Figure 3-4 demonstrated that albuterol did 
not significantly affect the expression of the selected miRNAs, which is consistent with our 






Donor 1 Donor 2 Donor 3
FC FC FC
miR-99b 2.6 none miR-99b 2.6
miR-191 2.2 miR191 2.5
miR-99a 2.3 miR-199 2.2
miR-4792 2.2
Fold change<2
Donor 1 Donor 2 Donor 3
FC FC FC
miR-199a 0.1 miR-199a 0.3 miR-3184 0.5





Figure 3-4. qPCR validation of effects of 1µM albuterol on miRNA expression.  
 
HASM cells from three donor cell lines were treated with 1µM albuterol for 18 hours and RNA 
was extracted for qRT-PCR analysis of the expression level of miR-99b, miR-191 and miR-199. 
miRNA expression levels were normalized against U6. Error bars represent standard error (n=3). 
 
 
Albuterol and dexamethasone induced changes in mRNA gene expression 
Another possible explanation for the lack of miRNA expression change could be that the 
dose used was too mild to produce any change at the transcription level; therefore, we tested the 
expression of several positive control genes that other studies have reported to change upon 
dexamethasone and albuterol treatments. For the 1µM albuterol treatment, we examined IL-8 
and IL-6, which are genes that have a CREB responsive element in its promoter and have been 
reported to be induced by β-agonists [30, 31]. We also examined RGS5, which is a gene reported 
to be down regulated by β-agonists [32]. Despite the big cell line to cell line variation, we 
observed close to 9 fold induction in IL-8 expression, a 1.5-2 fold induction in IL-6 expression 
and a slight decrease in RGS5. These results suggest the albuterol treatment conditions were 83 
 
sufficient to cause mRNA level changes; however, the magnitude of change varied significantly 
between donors (Figure 3-5).  
 
 
Figure 3-5. Effects of 1µM albuterol on mRNA expression.  
 
HASM cells from 3 donor cell lines were treated with 1µM albuterol for 18 hours and RNA was 
extracted for qRT-PCR analysis. mRNA expression was normalized to beta-actin. Error bars 
represent standard error (n=3). 
 
For dexamethasone, we tested CRISPLD2, KCTD12, PTX3, SERPINA3, and C13orf15, 
which are top differentially expressed transcripts identified in a parallel RNA sequencing project 
(Himes et al., submitted). KCTD12, PTX3 and SERPINA3 are canonical GR responsive genes 
that contain either negative GRE or positive GRE elements in its promoter [33-35]. These genes 
are known to be either suppressed or induced by dexamethasone treatment. CRISPLD2 and 
C13orf15 were novel GR responsive genes that were identified through our total RNA 84 
 
Sequencing project (Himes et al. submitted). Similar to the IL-8 finding, we observed big inter-
donor variations between cell lines under dexamethasone treatment. CRISPLD2, PTX3, 
SERPINA3 were induced by ~2-10 fold upon 1μM dexamethasone treatment, whereas KCTD12 
which is known to contain a negative GRE in its promoter was suppressed by ~80% (Figure 3-6). 
These data suggest that both 1μM albuterol and dexamethasone treatments were sufficient to 
elicit transcriptional changes at the mRNA level. 
 
 
Figure 3-6. Effects of 1µM dexamethasone on mRNA expression.  
 
HASM cells from 3 donor cell lines were treated with 1µM dexamethasone for 18 hours and 
RNA was extracted for qRT-PCR analysis. mRNA expression was normalized to beta-actin. 









Individual microRNAs can regulate gene expression by targeting over 100 mRNAs, and 
thus microRNAs can have vast effects in transcriptome regulation [14, 36, 37]. Although more 
than 1000 miRNAs have been discovered, the biological functions for a majority of miRNAs 
remain undetermined [14, 36]. This is especially true regarding the role of miRNAs in the 
pathogenesis of a complex disease like asthma and the role they play in regulating asthma drug 
response. Next-generation small RNA sequencing allows for comprehensive and quantitative 
profiling of miRNAs in a sample. Compared to previous microarray and qPCR based miRNA 
profiling studies in airway smooth muscle and the lung; this is the first sequencing study of ASM 
and thus offers better broader coverage of miRNAs in this cell type. Using next-generation small 
RNA sequencing, we examined the effects of the two mainstay asthma therapies on the 
microRNA transcriptome in HASM cells.  
β-agonists and corticosteroids are both known to have profound effects on gene 
transcription. Corticosteroids mediate their anti-inflammatory effects through the activation of 
glucocorticoid receptors (GRs). Once activated, GRs translocate into the nucleus to bind directly 
to DNA to modulate transcription. GRs can enhance or interfere with NF-kB mediated gene 
transcription [38, 39]. β-agonists are potent bronchodilators that activate gene transcription via 
cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) [30-32]. It 
is conceivable that when GR and CREB are both activated they interact with each other to 
modulate both DNA binding and transcription. In our study, 1µM treatment of β-agonist, 
corticosteroid and combined treatment for 18 hours did not cause significant changes in miRNA 86 
 
expression. However, under the same treatment conditions, we observed significant changes in 
genes known to be affected by β-agonists and corticosteroids. 
The lack of miRNA expression changes is consistent with an existing profiling study that 
examined the effect of corticosteroids on miRNA expression in the lung, in which miRNA levels 
before and after a 4-week budesonide (a type of corticosteroid) treatment were compared [40]. 
Lung biopsy was used to collect airway smooth muscle and 227 miRNAs were interrogated by 
direct qRT-PCR. No significant differences in miRNA were detected between the before and 
after the treatment [40]. Compared to the 227 miRNA covered by this previous study, we tested 
all miRNAs expressed in HASM giving us a much broader picture of miRNA expression. 
Consistent with the previous study, our findings suggest that miRNA expression is not altered by 
corticosteroids. Since corticosteroids are known to have profound effects on gene transcription 
and our parallel mRNA sequencing study indicated the same treatment conditions induced 
differential expression in 316 mRNAs (Himes et al, submitted), this lead us to speculate that 
perhaps the control of miRNA processing may have a bigger impact on miRNA expression 
rather than transcriptional changes of its primary transcript. This theory is consistent with several 
studies looking at the effect of corticosteroids in lymphocytes. In lymphocytes, corticosteroids 
were found to suppress several important miRNA processors in the processing pathway – 
including Dicer, Drosha and DGCR8/Pasha – to cause global repression of miRNAs [41, 42]. 
Although this effect of corticosteroids on the processing machinery is likely cell type specific 
and may not be present in HASM cells. 
A recent study by Gantier et al. determined the half-life of miRNAs at around 5 days, 
making them more than 10 times more stable than mRNAs[43]. The differences in half-life 
between miRNA and mRNAs may explain the lack of changes in miRNAs we detected. Perhaps 87 
 
a longer treatment window would have given observable changes. If an extended time window is 
needed to observe changes in miRNA expression, then it raises another important question about 
how miRNAs respond to external stimuli and mediate stress responses if their expression 
remains stable for days. Perhaps there are other mechanisms (other than expression changes) that 
allow miRNAs to quickly respond to external cues and mediate their downstream regulation. 
In conclusion, our results combined with other studies suggest that unlike mRNAs, 
miRNAs are much more stable and cannot be easily induced transcriptionally under the 
treatment conditions we used. It is unlikely that miRNAs comprise novel asthma drug responsive 
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The pathophysiology of asthma is characterized by airway inflammation, remodeling and 
hyper-responsiveness.  microRNAs (miRNA)  are well recognized important gene fine tuners 
and they are known to play important role in regulating basic cellular functions such as cell 
proliferation. The first part of this thesis was aimed to explore the role of miRNAs in the 
regulation of critical ASM phenotypes and shed lights on potential new asthmatic therapeutic 
targets. The second half of the thesis was aimed to explore whether miRNAs expression is 
influenced by conventional asthma treatments.  
In chapter 2, we used next-generation sequencing to establish the baseline expression 
profiles of miRNAs in human airway smooth muscle cells (HASM) followed by functional 
studies characterizing the role of miR-10a, the most abundant miRNA in HASM cells. Through 
an unbiased genomic approach, we demonstrated that miR-10a inhibits HASM cell proliferation 
by inhibiting the PI3K pathway. The significance of this finding is going to be discussed in 
details below.  
In chapter 3, surprisingly, we found that miRNA expression was not changed upon the 
treatment of conventional asthma treatments (β-agonists and corticosteroids), which both are 
known to induce transcriptional changes in mRNA expression. Under the same treatment 
condition, we demonstrated that both treatments induced changes at the mRNA level. This 
finding suggests β-agonists and corticosteroids do not change miRNA expression. From a 
microRNA regulation perspective, our result suggest that miRNAs are not transcriptionally 




The role of miR-10a in regulating airway smooth muscle biology 
  In chapter 2, we used next-generation sequencing to uncover the baseline miRNA 
expression profile in primary human airway smooth muscle cells (HASMs). We discovered a 
specifically enriched miRNA, miR10a, whose expression accounts for approximately 25% of all 
annotated small RNA sequences detected. We then employed an unbiased genomic approach, to 
assess the potential role of miR-10a in airway smooth muscle cells. We used miRNA mimics as 
a tool to genetically alter miR10a abundance in HASM cells and whole genome microarray 
analysis to identify differentially expressed genes resulting from elevated miR10a levels. Gene 
set enrichment analysis was then performed on the hits to unravel the biological function of miR-
10a in HASM cells. 
While miR-10a is ubiquitously expressed, its expression in HASM is far higher than in 
all other tissues tested including airway epithelial cells. A recent study found that 60% of all 
miRNAs expressed at relatively low levels exert little effect on gene expression and are thus 
essentially non-functional [1], suggesting that only highly abundant miRNAs can mediate the 
majority of miRNA-related target gene suppression events. Moreover, miRNAs exhibiting tissue 
and cell type enriched expression patterns often play important roles in that tissue or cell type. 
For example, miR-1a, which is highly enriched and abundant in the heart, regulates cardiac 
remodeling [2, 3]; and miR-122a, which accounts for 78% of all miRNAs in the liver, controls 
multiple processes critical for hepatic function [4].  Consistent with these findings we discovered 
that miR-10a regulates HASM proliferation by inhibiting the expression of phosphoinositide 3-
kinase (PI3K) and its downstream signaling. 
As a follow up study, we have also tested the role of miR-10a in regulating the contractile 
phenotype of HASM cells. Alpha-smooth muscle actin (α-SMA) is an ASM cell-specific marker 94 
 
and its expression level correlates strongly with the contractility response of ASM cells in-vitro 
[5-7]. We used α-SMA as a molecular surrogate for the contractile phenotype of ASM, and have 
observed that miR-10a inhibitors consistently caused an up regulation of a 2-3 fold increase in α-
SMA compared to the inhibitor controls (data not shown). We have also obtained some 
physiological data suggesting that inhibition of miR-10a led to a 75% greater increase in TGF-β1 
induced ASM contractility as measured by Traction Force Microscopy (data not shown).  These 
preliminary results suggest that miR-10a also regulates the contractile phenotype of HASM 
through an unknown mechanism. Investigating the molecular mechanism of miR-10a’s 
regulation of contractility could be difficult since the molecular pathways that regulate cell 
contractility are not as well characterized and multiple parallel pathways appear to control 
contractility. However, it is interesting to note that a recent study suggests that the activation of 
AKT1 and its downstream signaling have led to a 6-fold increase in α-SMA expression [8]. This 
is consistent with our data as it is conceivable that miR-10a also regulates α-SMA expression 
thorough AKT1 activation by PI3K signaling. 
In the future, it will be interesting to characterize the in-vivo function of miR-10a in one 
of the allergic asthma models. Our in-vitro data suggest that miR-10a is a potential regulator of 
both the proliferative and contractile phenotypes of ASM, which are the main drivers behind 
airway remodeling and asthma pathogenesis. 
 
Therapeutic potential of targeting miR-10a to treat asthma 
  ASM is the critical effector tissue in maintaining bronchomotor tone, and phenotypic 
changes in ASM play pivotal roles in the pathogenesis of a variety of lung diseases [9]. An 
increase in ASM tissue mass is a major driver of airway narrowing, which is associated with 95 
 
asthma [10-13]. The mainstay therapies for asthma mainly involve the use of bronchodilators and 
anti-inflammatory agents. ASM remodeling remains a symptom not well managed by these 
conventional therapies [14, 15]. Therefore, the regulatory role of miR-10a in ASM proliferation 
raises an interesting therapeutic potential for miR-10a targeting.  
  In a follow up study to explore the possibility that dysregulation of miR-10a levels is 
involved in asthma pathogenesis, we tested the hypothesis that miR-10a levels is differentially 
expressed between normal and asthmatic patients. As a pilot study, we used quantitative RT-
PCR (qRT-PCR) and examined the expression level of miR-10a in HASM cells from ten healthy 
donors and ten asthmatics (data not shown). We did not observe significant changes in miR-10a 
expression between the two groups. The result does not rule out the role of miR-10a regulation in 
asthma pathogenesis because of several possible reasons including: 1) HASM from asthmatic 
patients was being cultured in vitro in an environment that lacks inflammatory cytokines and the 
extracellular matrix environment critical to maintain the asthmatic smooth muscle phenotypes. 2) 
The ten asthmatic HASM samples were from patients with variable asthma severity, ranging 
from mild to severe. A detectable difference may be found in a severe asthmatic population. 3) 
Lastly, just like in any gene expression analysis, there might be big underlying inter-individual 
variability in miR-10a expression level may mask a trend and necessitate a bigger sample size to 
detect a significant difference. Because our data did not show any borderline significant changes, 
the lack of significance result is unlikely to be due to the sample size. 
 
Significance of miR-10a’s targeting of PI3K 
Our study is the first to experimentally identify a miRNA as a direct regulator of PIK3CA, 
which is a central component of the PI3K signaling pathway. Both miR-10a and PI3K are highly 96 
 
evolutionarily conserved and are ubiquitously expressed in many other cell types. We predict 
that miR-10a regulation of PI3K also plays important biological roles in tissues other than ASM.  
With the growing popularity of conducting miRNA expression profiling studies in tumor 
tissue and cell lines, miR-10a has been implicated in multiple studies on tumorigenesis [16-24]. 
In particular, miR-10a has been implicated in development of cancer and patient survival; its 
expression is frequently altered in several cancers including lung cancer, breast cancer and colon 
cancer, and its expression level correlates with patient survival [25-29]. In a more recent study, 
miR-10a knockout transgenic mice displayed a greater frequency of intestinal carcinoma [25]. 
This is highly relevant given that PI3K is one of the most frequently dysregulated signaling 
pathways in cancer [30]. It is possible that alteration in miR-10a expression may contribute to 
abnormal PI3K signaling in cancer and thus making miR-10a an attractive drug target for cancer 
therapy or biomarker for cancer progression. In the future, exploring the miR-10a-PI3K link in 
different cancer model further will extend the implications of our current study and may yield 
important mechanistic insights into cancer cell proliferation. 
 
Perspectives in miRNA research 
  Nearly 97% of the human genome is non-coding and miRNAs are a group of non-coding 
RNAs that have been intensively studied over the past few year. The biggest obstacle in miRNA 
research is target identification since one miRNA can have more than 200 predicted mRNA 
targets. Computational algorithms have been the major prediction tool to identify miRNA target 
genes. These algorithms rely on the principle that most miRNAs mediate gene silencing via the 
binding of its seed sequence in the 3’untranslated region (3’UTR) of the target gene [31]. The 
algorithms typically scan the 3’UTRs of all known mRNAs and populates a list of potential gene 97 
 
targets with their associated targeting probabilities determined by the level of base pair matching 
and conservation[32]. It is widely recognized that different algorithms may yield different 
miRNA-mRNA pairing predictions and a large number of predicted target genes may be false 
positives or false negatives, which further complicates downstream functional studies. The 
biggest limitation of relying on computational algorithms is that the predictions are restricted in 
the 3’UTR; a large proportion of miRNA binding may occur in the coding region of the gene, 
which is not accounted for in current computational predictions [33]. Lastly, the prediction 
algorithms do not take into account tissue-specific targeting. It has become clear that miRNAs 
exhibit both tissue specific expression patterns and their targeting tends to also be highly tissue 
specific. In our study on miR-10a, we were the first to identify miR-10a’s profound effect on 
PI3K signaling although there have been multiple previous studies on miR-10a linking it to other 
cell signaling pathways in other cell types [18, 34].  
  Most recent studies use an experimental-based approach for target identification. Similar 
to what we did to study miR-10a, transfection of miR inhibitor and mimics followed by high 
throughput transcriptomic profiling is used. This approach has two serious limitations: first, it 
cannot differentiate between direct and indirect targets, a careful time course experiment is 
required to pick up the earliest window for primary change detection. Second, the targets 
identified through this approach will only include the targets changed at the transcriptional level. 
Recent progress in high-throughput proteomic studies, such as stable isotope labelling by amino 
acids in cell culture (SILAC), might offer intrinsic advantages in order to determine the effect of 
miRNAs on final protein outcome. 
  Despite of the fact that many miRNAs and their binding sites are highly conserved, 
which suggests an important biological function, most miRNA effects on target protein 98 
 
expression is around 2-fold. This is consistent with our observations of miR-10a’s effects on 
PIK3CA and cell proliferation. According to an emerging theory that miRNAs may act as fine-
tuning buffers to help the biological system avoid gene expression fluctuations and maintain 
homeostasis [35]. If this theory holds true, understanding the biological relevance of miRNA is 
perhaps still in its nascent stages. More functional miRNA studies are needed to help better 
shape the picture of miRNA-regulated gene networks and to define the big picture biological 
function miRNA. 
   It has been over twenty years since miRNA was first discovered in 1993. Despite the 
growing amount of research in this area since, the cellular functions of miRNAs are just 
beginning to be uncovered. The rapid development of high throughput and computational tools 
has facilitated the discovery of many novel miRNAs and has generated a huge amount of in-
silico data that have assisted in suggesting biological functions of miRNAs. However, relatively 
few in silico predictions can be functionally validated using experimental techniques. Therefore, 
combining computational and experimental approaches would greatly advance the identification 
of biologically relevant miRNA targets, which is essential for us to better understand miRNA 
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ABSTRACT 
The β2-adrenergic receptor (β2AR) is a prototypic G-protein coupled receptor (GPCR) 
that plays a critical role in lung physiology and disease. Agonists of the β2AR relax airway 
smooth muscle and are used by virtually all asthma patients to control bronchoconstrictive 
symptoms. The activation of β2AR is closely regulated and is attenuated by receptor down 
regulation, which is believed to be a major cause underlying the loss of efficacy in the prolonged 
use of β-agonists. Our laboratory has previously performed a genome-wide RNA interference 
(RNAi) based screen that identified a number of important regulators of β2AR expression. In this 
study, we focused on characterizing the top hit from the RNAi screen—AA496068 EST 
(AAEST), which is a previously un-characterized express sequence tag. We have confirmed the 
expression of AAEST using RT-PCR and other cloning techniques. We have also established 
AAEST as an important negative regulator of baseline β2AR expression in both the screening 
cell line and physiologically relevant primary airway smooth muscle cells. Overall, our results 
identify AAEST as a novel RNA regulator of β2AR expression and suggest a possibility of 











Asthma is an increasingly prevalent chronic lung disease that affects about 300 million 
people worldwide [1, 2]. Currently there is no real cure for the disease and most of the treatment 
options fall into either the rescue or the anti-inflammatory medication categories. All rescue 
medications are essentially -agonists that exert their effects by binding to 2 adrenergic 
receptors in the lung [3, 4] 
The β-adrenergic receptors are members of a family of seven transmembrane receptors 
that mediates signaling through a heterotrimeric G protein complex. There are three major 
groups of β-adrenergic receptors: β1, β2 and β3. Compared to other β-adrenergic receptors, the 
βARs are primarily found in the lung and are ubiquitously expressed in almost all types of lung 
cells, such as airway smooth muscle cells, epithelial, and type II cells [3]. 
Under normal physiological conditions, 2ARs expressed in the lung are the primary 
target of catecholamine hormones, such as epinephrine. Binding of agonists to the receptor 
activates the associated stimulatory G protein, leading to a signaling cascade that includes 
adenylyl cyclase activation, cAMP formation, and the subsequent protein kinase A (PKA) 
activation. Activated PKA then phosphorylates multiple downstream target proteins, resulting in 
reduction of intracellular calcium, ultimately leading to relaxation of airway smooth muscle cells, 
and bronchodilation [3, 5]. 
Adopting the physiological function of 2AR, -agonists are synthesized and used as a 
rescue medication to induce bronchodilation during an asthma attack, which is characterized by 
airway smooth muscle constriction that leads to narrowing of the airways. Activation of β2AR 
signaling by β-agonists is usually attenuated by desensitization and down-regulation of the 
receptor, which are important intrinsic cellular mechanisms that prevent continuous activation of 105 
 
the signaling pathway and ensures cell homeostasis [5]. Receptor desensitization happens within 
seconds of β-agonists binding to the receptor: β2ARs are rapidly phosphorylated by G-protein 
coupled receptor kinases (GRKs) leading to the recruitment of β-arrestins to the receptor. The 
interaction between β-arrestins and β2AR uncouples the activated G proteins and thus effectively 
turns off the downstream signaling. Prolonged stimulation of β-agonist leads to receptor down-
regulation or a loss of functional receptor expressed on the cell surface. β2AR down-regulation 
involves clathrin-mediated endocytosis of the receptor. After the receptor being endocytosed, it 
can either be recycled back to the cell surface, or it can to be sorted into the late endosome which 
will fuse with lysosome, leading to receptor degradation. A key determinant of this process is 
receptor ubiquitination, which is mediated by an ubiquitin E3 ligase and an adaptor protein [3, 5]. 
β2AR down-regulation which leads to permanent loss of receptors on the cell surface can 
have significant clinical implications especially for severe asthma patients that are regularly 
treated with long acting β-agonists [6]. The reduced receptor expression can lead to reduced 
smooth muscle cell relaxation and thus limit the efficacy of β-agonists therapy. Many adverse 
events could result because of decreased efficacy of treatment such as loss of asthma control and 
longer duration of exacerbation. Multiple pharmacogenomics association studies also 
demonstrated the importance of β2AR receptor regulation [6, 7]. Single nucleotide 
polymorphisms that display accelerated receptor degradation in vitro are shown to be associated 
with altered sensitivity of drug treatment. Because βAR regulation plays central role in 
determining the clinical response of β-agonists, it is critical to fully understand the molecular 
mechanism underlying the regulation of baseline β2AR expression and receptor down-regulation. 
Genome-wide functional screen offers a powerful approach for unraveling the molecular 
basis of human diseases and biological processes [8, 9]. RNA interference (RNAi) based gene 106 
 
silencing relies on the potent and specific gene suppression activity exhibited by small 
interfering RNA (siRNA) of 19-21nt or by short-hairpin RNAs [8]. The use of RNAi libraries, 
together with phenotype based functional assays has led to the identification of genes critical for 
a variety of biological processes, including cell growth, senescence and tumor development[10-
12]. Application of a powerful RNAi based screen offers big potential to uncover novel genetic 
regulatory pathways that are important in the regulation of β2AR expression and down-
regulation.  
To explore novel regulators of surface 2AR levels, we have developed a highly efficient 
genome-wide RNAi library covering approximately 80% of the entire human genome [13]. 
Using this RNAi library, together with a robust fluorescence-activated cell sorting (FACS)-based 
assay for measuring β2AR amount, we have conducted a surface 2AR level screen [13, 14]. 
The highly efficient screen revealed 11 novel genes, which have not been shown to play a role in 
the regulation of 2AR [13]. In this study we characterized AAEST which is the top hit from our 
RNAi screen. Our results identified AAEST as a novel non-coding RNA that suppresses the 










MATERIAL AND METHOD 
 
Mammalian cell culture and transfection 
Human embryonic kidney HEK293T and 293β2AR cells were cultured in DMEM (Invitrogen) 
containing 10% fetal bovine serum (FBS; Invitrogen), 4 mM glutamine, 100 U/ml penicillin, and 
100μg/ml streptomycin.  The HEK293 cells stably expressing N-terminal Flag-tagged β2AR 
(293β2ARWT) and stably expressing N-terminal Flag-tagged recycle-deficient β2AR (293β2AR) 
were kindly provided by Dr. Mark von Zastrow (UCSF). Primary human airway 
smooth muscle (HASM) cells were maintained in Ham’s F12 medium with 10% fetal calf serum 
(FCS) and antibiotics, and grown in DMEM supplemented with 1% FBS for isoproterenol(ISO) 
treatment. Passages 4 to 7 HASM cells were used in all experiments. Transfection of plasmid 
DNA into 293βAR cells was performed using TurboFect reagent (Fermentas). Transfection of 
siRNA was done using DharmaFECT1 reagent (Thermo Scientific). Non-targeting control 
siRNA and AAEST siRNA were purchased from Sigma-Aldrich. 
 
Flow cytometry analysis  
siRNA transfected 293β2AR cells (5x10^6) were cultured for 1 day in Opti-MEM (Invitrogen) 
containing 1%FBS and 10µM ISO for 16h to induce the down-regulation of β2AR. Cells were 
washed with PBS and incubated with diluted TrypLE Express Enzyme (1:10 dilution in PBS; 
Invitrogen) for exactly 1 min at room temperature before inactivation with complete medium. 
Cells were washed once with PBS containing 1%PBS to remove residual traces of TrypLE. Cells 
(1x10^7) were suspended in 1ml PBS containing 1%FBS and stained with 10µg/ml FITC-
conjugated anti-Flag M2 antibody (Sigma-Aldrich) on a rotary mixer for 30min. Cells were 108 
 
washed again and passed through 50-µm cell strainer to remove cell clumps before being 
measured using flow cytometry analysis on a FACS Canto II system (BD Biosciences).During 
flow cytometry analysis, gating was adjusted to measure the FITC (green) signal. Background 
auto fluorescence was identified by plotting FITC with SSC (side scatter) signal.  
 
Immunoblotting 
Transfected cells were washed with PBS and lysed with Nonidet P-40 lysing buffer (50mM Tris-
HCl, pH7.5, 150mM NaCl, and 0.5% Nonidet P-40) containing protease inhibitor (Roche). 
Protein samples were separated on NuPAGE 4-12% Bis-Tris gels (Invitrogen) and transferred to 
nitrocellulose membranes (Bio-Rad). Immunoblot signals were developed using SuperSignal 
West Pico/Femto Chemiluminescent Substrates (Pierce) and using X-ray films. Antibody used 
were β2AR (H20) (Santa Cruz), HA antibody (Sigma). 
 
3’ and 5’ RACE (rapid amplification of cDNA ends) 
3’ and 5’ RACE were performed using manufacturer’s recommended condition with a kit 
purchased from Invitrogen. In brief, for 5’ RACE, first strand synthesis was performed using 
gene specific primer (GSP) 92R, followed by dc tailing on the cDNA at the 5’ end. The product 
was further amplified with a nested GSP 114R and the commercial AAP primer for 30 cycles 
and lastly, the PCR product was enriched by another round of nested PCR reaction using primer 
97R and kit provided AUAP primer (30 cycles). For 3’ RACE, first strand synthesis was 
performed using kit provided AP primer, followed by a round of PCR with the primer set 109F 
and AUAP (30 cycles), the PCR product was further enriched by another round of nested PCR 
with primer set 110F and AUAP (30 cycles). End PCR products were resolved on a ethidium 109 
 
bromide stained 1.5% agarose gel at 100 volts for 30 min. DNA bands were cut off and purified 
using QIAquick gel extraction kit (Qiagen). All sequencing was performed at Genewiz. 
 
Small RNA cloning 
Total RNA were extracted from 293 cells using Trizol (Qiagen). RNAs were ligated with 
customer made adaptors on 3’ and 5’ adaptor (Epicentre).and PCR amplified for 30 cycles. 
Amplified DNA products were resolved on SDS-PAGE gel (Invitrogen) in TAE buffer 
(Invitrogen). Corresponding DNA bands were cut off, purified and sequenced (Genewiz). 
 
Northern blot 
Non-radioactive northern blot was performed using DIG-labeled probe system, DIG Northern 















RNAi-based screen identifies AAEST as a novel regulator in 2AR expression 
Our lab has developed a novel shRNA based RNAi library that contains an estimated 
600,000 individual shRNA-expressing lentiviral constructs targeting about 28,000 human genes 
(average over 20 different shRNAs per gene) [13]. We performed the RNAi screen on 2AR 
regulation using a mutant HEK293 cell line (PD Cells), in which the 2AR is stably expressed 
and can undergo efficient down-regulation upon agonist isoproterenol (ISO) stimulation [13]. In 
this cell line, the 2AR is N-terminally Flag-tagged and thus can be easily detected in flow 
cytometry using anti-FLAG antibodies. This flow cytometry-based assay offers a highly 
quantitative and efficient way to isolate cells with altered amount of surface 2AR. PD cells 
were transduced with a high-titer shRNA lentiviral library and a total of four rounds of FACS 
(fluorescence activated cell sorting) were performed to isolate cells that contain higher levels of 
cell surface 2AR. The FACS-enriched cells, displaying a higher amount of surface 2AR, 
potentially contain shRNAs that inactivate genes critically involved in 2AR regulation. To 
identify the corresponding shRNAs, we extracted genomic DNAs from these cells and performed 
genomic PCR [13]. 100 clones were sequenced and the gene hits are summarized below 
(Appendix-table-1). Most of the shRNAs target known annotated genes. However, strikingly, 34 
of the 100 sequenced shRNA clones correspond to AAEST, which is an expressed sequence tag 





Appendix-table 1. Top hits identified from β2AR RNAi screen 
 
 
AAEST knockdown increases 2AR expression  
We next validated the gene hit AAEST from the previously described shRNA-based 
RNAi screen using a different method of gene knockdown. We used two chemically synthesized 
siRNAs targeting two different regions of AAEST (AAESTsiRNA1 and AAESTsiRNA2). PD 
cells were transfected with the siRNAs along with a non-targeting siRNA control for 72 hours. 
The cells were then labeled with anti-FLAG-FITC and the cell surface 2AR (FLAG-tagged) 
amounts were quantified using flow cytometry analysis (signal is typically represented as mean 
FITC). The fold change in mean FITC in four different experiments was averaged and is shown 
below in Appendix- figure-1. Cells treated with AAEST siRNA2 showed a two-fold increase in 112 
 
surface 2AR amount, indicating that AAEST is functioning as an inhibitor of baseline 2AR 
expression. Only siRNA 2 had an effect on surface β2AR, this likely because of siRNA 1 
targeted a stretch of duplicated region which has high similarity with a genomic sequence on 
chromosome 15.  
 
 
Appendix-figure 1. Effect of AAEST knockdown on surface β2AR expression. PD cells were 
transfected with non-targeting siRNA (NT) , AAEST siRNA 1 (AAEST si1) or AAEST siRNA 2 
(AAEST si2) for 72 hours. Cells were stained with anti-FITC antibody and analyzed with flow 
cytometry. Error bars represent standard error (N=7). * represent significance compared with 
student t-test (P<0.05). 
 
We further determined the effect of AAEST knockdown on endogenous β2AR 
expression in primary human airway smooth muscle cells (HASM), which are the physiological 
target of β-agonists. HASM cells were transfected with the two previously described AAEST 
specific siRNAs and the total endogenous β2AR protein amount was measured by Western 
blotting. Consistent with the results obtained from PD cells, cells treated with AAEST siRNA2 
displayed the greatest increase in total β2AR (Appendix-figure-2). About two-fold increase in 113 
 
β2AR expression was observed in AAESTsi2-transfected HASM cells. A representative 
immunoblot is shown below (Appendix-figure-2). qRT-PCR was also performed to measure the 
mRNA level of β2AR. We found no significant difference in β2AR mRNA levels between the 
wild type and knockdown cells, suggesting the effect of AAEST on β2AR expression is not 
through transcriptional regulation (data not shown). 
 
 
Appendix-figure2. Effect of AAEST knockdown on total β2AR protein expression in HASM 
cells. HASM cells were transfected with non-targeting siRNA (NT) , AAEST siRNA 1 (AAEST 
si1) and AAEST siRNA 2 (AAEST si2) for 72 hours. Cells lysates were extracted and analyzed 
with immunoblot with anti-β2AR antibody. Protein amount was quantified using Image J. Error 






Cloning of the full length transcript of AAEST 
AAEST is an unannotated expressed sequence tag, which is likely to be a part of the 
larger RNA transcript.  We next examined the expression of the EST and attempted to clone the 
corresponding full-length transcript. We first used RT-PCR with multiple primers covering both 
the predicted intron and exon sequences (based on sequences from UCSC genome browser) to 
test whether AAEST is expressed in PD cells. Appendix-figure-3 is a sample RT-PCR result 
with multiple primers covering both predicted intron and exon sequences. All combinations of 
primers yielded specific amplification. This result not only confirms the expression of AAEST, 
but further suggests that the predicted sequence that includes AAEST is incomplete and is likely 
to constitute a much bigger transcript.  
 
 
Appendix-figure 3. RT-PCR of AAEST. RNAs were extracted from PD cells and amplified 
using RT-PCR with multiple primer sets spanning cross predicted intron and exon junction of the 
AAEST sequence.  115 
 
 
To further confirm the expression of this transcript, we used quantitative RT-PCR to 
compare the expression level of this transcript in regular reverse transcribed total RNA, reverse 
transcribed total RNA treated with RNase I and a without reverse transcriptase reaction control. 
Treatment of RNA with RNase I completely brought the signal from AAEST transcript to its 
background signal (data not shown). This result further confirmed the expression of AAEST 
transcript. We next performed 5’ and 3’ Rapid Amplification of cDNA Ends (RACE) to 
determine the 5’ and 3’ ends of the AAEST encoding transcript. All major amplicons from the 
reactions were sequenced. The red arrows indicate amplicons corresponding to the specific 
AAEST sequence (Appendix-figure 4). Combining results from the RACE reactions, we have 
successfully cloned the full-length 1.85Kb transcript, which includes the AAEST sequence 




Appendix-figure 4.  5’ and 3’ RACE of AAEST. RACE experiments at both ends were 




AAEST is unlikely to encode a protein or peptide 
Based on our preliminary data, a sequence analysis of the full-length transcript was 
performed to determine the nature of the transcript, which could potentially provide hints to 
determine the mechanism of regulation. Open reading frame (ORF) analysis revealed the biggest 
ORF is 579bp long (start with AUG), which can encode a 22KDalton protein which does not 
have any homology to known proteins. To test if the ORF is translated, we subcloned the ORF 
sequence with HA tag into a PCDNA 3.1+ vector and expressed HA-ORF with a positive control 
HA tagged protein (HA-ARRDC1). HA-ORF was not detected suggesting the ORF is not 
translated into a protein (data not shown). 
 
AAEST RNA does not encode microRNA 
Next, we tested the hypothesis that the AAEST transcript is a non-coding RNA. A 
secondary structure analysis was performed using the mfold software. Secondary structure 
analysis revealed that the transcript forms two very stable stem loops on the 5’end, reminiscent 
of most primary transcripts of microRNA (miRNA) (Appendix-figure 5). Prediction of mature 
miRNA sequences from the putative stem loops revealed potential seed sequences that are 
complementary to the mRNA of 2AR. Most human miRNAs are known to function by 
inhibiting the translation of their target transcripts [29-31]. Given the secondary structure 
analysis and our qRT-PCR result that knocking down AAEST does not affect the mRNA level of 
2AR, we hypothesized that AAEST may function as a primary transcript of a novel miRNA, 
which negatively regulates 2AR expression through translational repression.  117 
 
 
Appendix-figure 5. Predicted stem loop structure of AAEST. AAEST sequence was put into 
mfold for secondary structure analysis. SL-1 (left) and SL-2 (right). 
 
To test if AAEST is a primary transcript of a miRNA that inhibits 2AR expression, we 
transfected PD cells (HEK293 cells expressing Flag-2AR) with two plasmids containing the 
predicted stem loop sequences, SL1 and SL2, both of which could function as precursor miRNAs 
and also a full length AAEST to reverse the AASET knockdown  phenotype. The SL1, SL2 and 
full length sequences were subcloned into PCDNA3.1+, which has been previously demonstrated 
to be suitable to over-express miRNAs [32-34].  Cells were transfected independently with 
plasmids encoding SL1, SL2 and full length AAEST to test which predicted stem loop functions 
as a precursor miRNA. The transfected cells were assayed by anti-FLAG immunoblotting (data 
not shown) and FACS analysis for the total and surface amount of 2AR. An empty plasmid and 
miR-9 plasmid were included to serve as a transfection control. None of the overexpression was 118 
 
able to rescue the knockdown effect of AAEST on 2AR expression, suggesting neither SL1 nor 
SL2 are functional forms of AAEST and the full length we have cloned might be incomplete. 
 
We next used northern blot with probe targeting the predicted miRNA to detect its 
expression. We had probes designed for both SL1 and SL 2. MiR-9 was used as a positive 
control and U6 was used as a loading control. There was no detection of miRNA encoded by the 
predicted sequence. Appendix-figure 6 shows a representative blot for SL-1 probe. 
 
 
Appendix-figure 6. Northern blot analysis of AAEST transcript encoded miRNA. Lane 1 
was loaded with a mixture of human kidney, lung and trachea total RNA. Lane 2 was loaded 
with human brain total RNA. Lane 3 was loaded with 293T total RNA. Probe targeting miR-9, 
U6, and AAEST-SL1 was used for small RNA detection. 
 
Since miRNA detection using northern blot depend heavily on the expression level of 
such RNA; therefore, we used 4 different cloning strategies to clone AAEST encoded miRNA 119 
 
using a PCR based method. In order to take into consideration of the different efficiency in 
miRNA processing, from its precursor form to the mature form, we have designed multiple 
primers to cover both forms. Appendix-table 2 summarizes the cloning efforts as well as the 
different positive controls that were used for each experiment. As shown in Appendix-table 2, we 
were unable to clone any mature miRNA or miRNA precursors encoded by the AAEST 
transcript while all the positive controls were successfully cloned.  In the deep sequencing of 
small RNAs in Chapter 3, we did not detect a small RNA or microRNA that originates from the 
AAEST RNA locus. Taken all the data together, we concluded of AAEST encodes neither a 
protein nor a miRNA, and thus likely is a novel long non-coding RNA.  
 




We performed a genome wide genetic screen to identify genes whose inactivation leads 
to impaired β2AR down regulation  using a novel RNAi platform combined with a robust flow 
cytometry based β2AR receptor quantification assay. Our screen has identified many genes that 
have not been previously recognized to play a role in the β2AR down regulation process, thus 120 
 
revealed many novel mechanisms of β2AR regulation. Several genes from the top hit list was 
successfully confirmed and characterized [13, 15]. In this study, we focused on characterizing 
the top hit from the screen- AAEST, an expressed sequence tag. Our results have established that 
AAEST is a novel transcript and this previously uncharacterized transcript plays an important 
role in inhibiting the baseline expression of 2AR. Moreover, we have confirmed the inhibitory 
effect of AAEST on β2AR in primary human airway smooth muscle cells, which is a cell type 
that is more physiologically relevant and directly controls bronchoconstriction. We also 
performed mechanistic studies to unravel how AAEST regulates β2AR expression. Our ORF 
experiment suggested that the predicted ORF encoded by AAEST was not translated and 
expressed. We also tested the possibility of AAEST gets processed into small RNAs to function 
as a miRNA and the various cloning results demonstrated it is unlikely that AAEST is processed 
into small RNAs. Hence, we have excluded the possibility of AAEST being a coding transcript 
and miRNA, we conclude that AAEST is likely to function as a long non-coding RNA that 
negatively regulates baseline β2AR expression.  
β2AR expression level directly affects the efficacy of β-agonist based bronchodilator 
therapy; therefore,  many past studies focused on dissecting the molecular mechanism of agonist 
induced receptor down regulation which involves receptor ubiquitination, internalization and 
lysosomal degradation [16-18]. Recently, RNA regulated protein expression has been a popular 
area of study. Non-coding RNAs has been shown to have profound effect on gene transcription 
and protein translation [19]. Within non-coding RNAs, miRNAs are predicted to regulate half of 
the mammalian genes [20]. Distinct from the traditional notion of agonist induced receptor 
phosphorylation and ubiquitination, Let7f miRNA was the first non-coding RNA shown to 
regulate baseline β2AR expression through the binding of its seed sequence to the 3’UTR of 121 
 
β2AR, which represents a novel mechanism of how β2AR protein expression is regulated [21]. 
Our study again provides another line of evidence highlighting the importance of non-coding 
RNAs on the regulation of baseline β2AR expression. Our finding is the first study showing 
evidence of a long non-coding RNA’s regulation of β2AR; however, the mechanism of how this 
long non-coding RNA regulates β2AR protein expression remains elusive.  
In the future, it is important to define and confirm the full length transcript of AAEST. 
Although we used the classical 5’ and 3’ RACE experiment to define the ends of AAEST 
transcript, there remains the possibility that this transcript extend further to the previously 
defined region since the 5’ end of AAEST genomic sequence contains a long repetitive sequence 
that is AT rich which could have interfered with our RACE efficiency. A northern blot 
experiment will be very useful to confirm the full length of this transcript and examine if there 
are multiple splice variants of AAEST. However, we think the possibility of AAEST having 
multiple splice variant is low since only the predominant band from the RACE experiment 
turned out to match the genomic sequence of AAEST. For follow up mechanistic studies, we 
believe a microarray experiment on control and AAEST knockdown samples will be very useful 
to examine the downstream consequence of AAEST’s regulation on β2AR and test if this novel 
non-coding RNA is a direct regulator of β2AR expression. In addition to AAEST, we have 
identified several other new regulators of β2AR down-regulation. However, we did not identify 
any of the bona-fide regulators of β2AR down regulation such as β-arrestin and NEDD4 E3 
ligase. This may be partly due to we sequenced only a partial fraction of the sorted cell 
population from the screen; therefore, sequencing the entire sorted cell population using the 
increasingly affordable deep-sequencing technology should help us to uncover more genes and 
reveal more insight into the regulators of β2AR down regulation. 122 
 
β-agonist is a mainstay therapy for asthma and there are several limitations to this 
treatments such as chronic use of long acting β-agonists in severe asthmatic population causes 
receptor desensitization and down regulation which as a result significantly reduces the efficacy 
of this treatment. Second, there is significant inter-individual variability in drug response among 
patients across all levels of severity, which is most likely due to variability in the receptor 
expression and signaling regulation. Therefore, reduction in functional β2AR numbers can 
directly cause loss of bronchodilator effect of β-agonists and result in longer duration of asthma 
exacerbation. Targeted inhibition of genes regulating β2AR baseline expression and down 
regulation provide a novel approach to improve the efficacy of β-agonists in asthma treatment. 
Our finding on AAEST along with other genes uncovered by the RNAi screen provided the basis 
for future in-vivo studies to examine the effect of these genes on improving the efficacy of β-
agonist based therapy. 
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